PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8136311-7	1994	In addition, the distinct difference in the pattern of response to the combination of 1,25(OH)2D3 with GM-CSF compared with that of 1,25(OH)2D3 plus IFN suggests that the augmentation of 1,25(OH)2D3 effect by IFN and GM-CSF is mediated by separate mechanisms.	25(oh)2d3	88-97	colony stimulating factor 2	Homo sapiens	103-109
8161795-2	1994	In the present study, we investigated a possible role of macrophage colony-stimulating factor (M-CSF) in 1 alpha,25(OH)2D3-induced proliferation of human circulating monocytes and the effects of 1 alpha,25(OH)2D3 on M-CSF production by human monocytic cells.	25(oh)2d3	113-122	colony stimulating factor 1	Homo sapiens	95-100
8136311-7	1994	In addition, the distinct difference in the pattern of response to the combination of 1,25(OH)2D3 with GM-CSF compared with that of 1,25(OH)2D3 plus IFN suggests that the augmentation of 1,25(OH)2D3 effect by IFN and GM-CSF is mediated by separate mechanisms.	25(oh)2d3	88-97	interferon alpha 1	Homo sapiens	209-212
8394128-4	1993	Alkaline phosphatase treatment of immunoprecipitated VDR from 1,25(OH)2D3-treated cells converts the form of the VDR with reduced mobility to the faster migrating species present in 1,25(OH)2D3-deficient cells.	25(oh)2d3	64-73	vitamin D receptor	Rattus norvegicus	53-56
8261414-3	1993	The production of GM-CSF by bulk cultures of enzymatically dissociated LLC-LN7 tumors that had been excised as s.c. tumors from mice was also blocked when the dissociated tumor was cultured with 1,25(OH)2D3 plus IFN-gamma.	25(oh)2d3	197-206	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	18-24
8394128-4	1993	Alkaline phosphatase treatment of immunoprecipitated VDR from 1,25(OH)2D3-treated cells converts the form of the VDR with reduced mobility to the faster migrating species present in 1,25(OH)2D3-deficient cells.	25(oh)2d3	64-73	vitamin D receptor	Rattus norvegicus	113-116
8224760-8	1993	Harderian gland VDR is at a lower concentration yet shows a markedly higher affinity and selectivity to 1,25(OH)2D3 than that of the intestine and kidney.	25(oh)2d3	106-115	vitamin D3 receptor	Heterocephalus glaber	16-19
8393296-5	1993	Despite these large differences in binding affinities for the VDR, AT and BT produced similar concentration-dependent increases in [Ca2+]i and in IP3 formation while 1,25(OH)2D3 was approximately 10-fold less active.	25(oh)2d3	168-177	vitamin D receptor	Homo sapiens	62-65
1800003-4	1991	OCT was also active in vivo, and, like 1,25(OH)2D3, decreased the pre-pro(PTH) mRNA levels.	25(oh)2d3	41-50	parathyroid hormone	Rattus norvegicus	74-77
1476184-2	1992	After stimulation with various doses of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3; 10(-11) to 10(-9) M], osteocalcin was consistently lower in the culture medium of ROS 17/2 osteoblastic cells conditioned with 5 microM Al(3+)-saturated transferrin (AlTR) than in apotransferrin (ApoTR)-treated controls.	25(oh)2d3	68-77	bone gamma-carboxyglutamate protein	Homo sapiens	101-112
2009668-2	1991	This review summarizes current knowledge on the distribution of the vitamin-D-dependent, calcium-binding protein, calbindin-D9k, an indicator of 1,25(OH)2D3 action, in mineralized tissues, with emphasis on the cellular and subcellular distribution of the protein.	25(oh)2d3	147-156	S100 calcium binding protein G	Homo sapiens	114-127
1657330-5	1991	Of the studied hormones, only 1,25(OH)2D3 was alone able to stimulate the synthesis and secretion of osteocalcin.	25(oh)2d3	32-41	bone gamma-carboxyglutamate protein	Homo sapiens	101-112
1800003-4	1991	OCT was also active in vivo, and, like 1,25(OH)2D3, decreased the pre-pro(PTH) mRNA levels.	25(oh)2d3	41-50	plexin A2	Mus musculus	0-3
1769236-4	1991	Tropoelastin levels in culture media and cell layers, as measured by an enzyme-linked immunoassay, decreased in a dose and exposure dependent manner after treatment with 1,25(OH)2D3; 24,25(OH)2D3 had no effect on tropoelastin production relative to solvent-treated controls.	25(oh)2d3	172-181	elastin	Bos taurus	0-12
2108798-8	1990	The MGP synthesized by the 1,25(OH)2D3-treated ROS 17/2 cells was identical to that found in bone by northern blot analysis of message and by western blot analysis of the media antigen.	25(oh)2d3	29-38	matrix Gla protein	Homo sapiens	4-7
1865969-7	1991	The elevated concentration of phosphate in renal failure may override PTH as a regulator of the renal 1,25(OH)2D3 formation.	25(oh)2d3	104-113	parathyroid hormone	Homo sapiens	70-73
34593422-6	2021	The inhibitory effect of 25(OH)D3 on cell proliferation was potentiated after inhibition of CYP17B1 and CYP24 by genistein, preventing further metabolism of 25(OH)D3 to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3).	25(oh)2d3	242-251	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	104-109
34534339-4	2021	Uptake of 25(OH)D3 led to a significant upregulation of vitamin D metabolizing CYP24A1 mRNA levels, indicating that kidney organoids possess a feedback mechanism to control active vitamin D (1,25(OH)2D3) levels.	25(oh)2d3	193-202	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	79-86
2537025-2	1989	Elevated arterial blood ionized calcium (Ca2+) inhibits the PTH-stimulated pathway for 1,25(OH)2D3 production.	25(oh)2d3	89-98	parathyroid hormone	Rattus norvegicus	60-63
34980721-1	2021	CYP24A1 regulates serum vitamin D (VD) levels by inactivating 25(OH)2D3, which is the precursor of the active form of VD (1alpha,25(OH)2D3), and CYP24A1 expression is controlled by multiple calcemic factors such as 1alpha,25(OH)2D3, calcium, and phosphate.	25(oh)2d3	62-71	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
34980721-1	2021	CYP24A1 regulates serum vitamin D (VD) levels by inactivating 25(OH)2D3, which is the precursor of the active form of VD (1alpha,25(OH)2D3), and CYP24A1 expression is controlled by multiple calcemic factors such as 1alpha,25(OH)2D3, calcium, and phosphate.	25(oh)2d3	129-138	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
34980721-1	2021	CYP24A1 regulates serum vitamin D (VD) levels by inactivating 25(OH)2D3, which is the precursor of the active form of VD (1alpha,25(OH)2D3), and CYP24A1 expression is controlled by multiple calcemic factors such as 1alpha,25(OH)2D3, calcium, and phosphate.	25(oh)2d3	222-231	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
34980721-1	2021	CYP24A1 regulates serum vitamin D (VD) levels by inactivating 25(OH)2D3, which is the precursor of the active form of VD (1alpha,25(OH)2D3), and CYP24A1 expression is controlled by multiple calcemic factors such as 1alpha,25(OH)2D3, calcium, and phosphate.	25(oh)2d3	222-231	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	145-152
3150956-2	1988	The thyrotropic secretory response to TRH was inhibited by a single intravenous dose of 50 U synthetic salmon calcitonin or trifluoperazine administered by mouth seven days prior to the TRH test, 6-12 mg/day, and stimulated by 1,25(OH)2D3 administered by mouth four days before the TRH test -3 micrograms/day.	25(oh)2d3	229-238	thyrotropin releasing hormone	Homo sapiens	38-41
3425161-5	1987	The TRH-induced PRL secretion was increased in cells incubated with 1,25(OH)2D3 for 144 h (0.766 +/- 0.061 vs 1.024 +/- 0.076 microgram/well, P less than 0.05; mean +/- SEM) compared with control cells.	25(oh)2d3	70-79	prolactin	Rattus norvegicus	16-19
2979828-3	1988	K-DR (24R,25(OH)2D3 (prepared by Kureha Chemical Ind.)	25(oh)2d3	10-19	kinase insert domain protein receptor	Mus musculus	0-4
3002965-7	1985	The minimal effective dose varied between experiments and ranged from 10(-11) to 10(-8) M. Moreover, proliferation (3H-TdR incorporation) of mouse thymocytes treated with phytohemagglutinin and IL 1 was decreased in a dose-dependent fashion by 1,25(OH)2D3 starting at 10-11) M. This effect might be secondary to a decrease of endogenous IL 2 production.	25(oh)2d3	246-255	interleukin 1 complex	Mus musculus	194-198
3105848-7	1987	The present results can be explained by the dual action of 1,25(OH)2D3 on both synthesis and release of BGP by bone turnover, whereas 24,25(OH)2D3 stimulates synthesis and accumulation of BGP in bone.	25(oh)2d3	61-70	bone gamma-carboxyglutamate protein	Rattus norvegicus	104-107
3780535-1	1986	The in vivo stimulation of vitamin D-dependent calcium-binding protein (9 K CaBP) synthesis by 1,25-dihydroxycholecalciferol [1,25(OH)2D3] in the rat duodenum has been analyzed using a specific [32P]complementary DNA probe for rat 9 K CaBP and inhibitors of RNA transcription (actinomycin D, alpha-amanitin) or protein synthesis (cycloheximide).	25(oh)2d3	128-137	S100 calcium binding protein G	Rattus norvegicus	76-80
3509739-2	1986	Enzyme activities were monitored for 72 h. 1,25(OH)2D3 but not 24R,25(OH)2D3 enhanced the activity of ODC in duodenum and bone.	25(oh)2d3	45-54	ornithine decarboxylase 1	Rattus norvegicus	102-105
3509739-2	1986	Enzyme activities were monitored for 72 h. 1,25(OH)2D3 but not 24R,25(OH)2D3 enhanced the activity of ODC in duodenum and bone.	25(oh)2d3	67-76	ornithine decarboxylase 1	Rattus norvegicus	102-105
3937588-3	1985	PTH stimulated CKBB in the osteoblast-like clone ROS 17/2; 1 alpha,25(OH)2D3 inhibited this activity while PGE2, CT and 24R,25(OH)2D3 had no significant effect.	25(oh)2d3	67-76	parathyroid hormone	Rattus norvegicus	0-3
3937588-3	1985	PTH stimulated CKBB in the osteoblast-like clone ROS 17/2; 1 alpha,25(OH)2D3 inhibited this activity while PGE2, CT and 24R,25(OH)2D3 had no significant effect.	25(oh)2d3	67-76	creatine kinase B	Rattus norvegicus	15-19
3498842-2	1987	Thus, while they had no effect in the system alone, both 1,25(OH)2D3 and 25(OH)D3 caused a dose-dependent potentiation of PTH-stimulated glucose 6-phosphate dehydrogenase activity in the hypertrophic chondrocytes of the rat metatarsal.	25(oh)2d3	59-68	parathyroid hormone	Rattus norvegicus	122-125
3498842-2	1987	Thus, while they had no effect in the system alone, both 1,25(OH)2D3 and 25(OH)D3 caused a dose-dependent potentiation of PTH-stimulated glucose 6-phosphate dehydrogenase activity in the hypertrophic chondrocytes of the rat metatarsal.	25(oh)2d3	59-68	glucose-6-phosphate dehydrogenase	Rattus norvegicus	137-170
3893009-7	1985	In non-diabetic rats, PTH administration significantly increased renal 1,25(OH)2D3 production (11 +/- 2 vs 46 +/- 5 pg/min/g; P less than 0.05).	25(oh)2d3	73-82	parathyroid hormone	Rattus norvegicus	22-25
3879241-4	1985	Thus, the reduction of proliferative response of MNC to PHA by 1,25(OH)2D3 appeared to have resulted from the inhibitory effects of the agent on both IL 2 and IL 1 production.	25(oh)2d3	65-74	interleukin 2	Homo sapiens	150-154
3879241-4	1985	Thus, the reduction of proliferative response of MNC to PHA by 1,25(OH)2D3 appeared to have resulted from the inhibitory effects of the agent on both IL 2 and IL 1 production.	25(oh)2d3	65-74	interleukin 1 alpha	Homo sapiens	159-163
6423272-3	1984	Application of 1 micrograms 1 alpha, 25(OH)2D3 within 30 min before or after treatment with 10 micrograms TPA caused about 72% inhibition of ODC induction at 4 hr.	25(oh)2d3	37-46	ornithine decarboxylase, structural 1	Mus musculus	141-144
6435838-2	1984	1.25 dihydroxycholecalciferol (1,25(OH)2D3), 5 X 10(-10)-2.5 X 10(-8) M, consistently decreased rPTH secretion in dose-related manner; the effect reached steady state after 24 h in vitro addition of 1,25(OH)2D3 and was also observed at different medium calcium concentrations (0.75, 1.25, 1.75 mM).	25(oh)2d3	33-42	parathyroid hormone	Rattus norvegicus	96-100
32189072-3	2020	The production of FGF23 is controlled by different factors including parathyroid hormone, 1,25(OH)2D3, alimentary phosphate, insulin, inflammation, and AMP-dependent kinase (AMPK) regulation of store-operated Ca2+ entry (SOCE).	25(oh)2d3	92-101	fibroblast growth factor 23	Rattus norvegicus	18-23
6546644-4	1984	In normal rats only 75 ng of 1,25(OH)2D3 increased calcium J net above vehicle control values (12 +/- 2 vs. 38 +/- 4 nmol X cm-2 X h-1, P less than 0.001).	25(oh)2d3	31-40	solute carrier family 6 member 2	Rattus norvegicus	61-64
33288743-6	2020	As ZK168281 also blunts 1alpha,25(OH)2D3-induced VDR signaling in fibroblasts of a patient with impaired vitamin D degradation, this VDR antagonist represents a promising therapeutic option for 1alpha,25(OH)2D3-induced hypercalcemia.	25(oh)2d3	31-40	vitamin D receptor	Homo sapiens	49-52
33288743-6	2020	As ZK168281 also blunts 1alpha,25(OH)2D3-induced VDR signaling in fibroblasts of a patient with impaired vitamin D degradation, this VDR antagonist represents a promising therapeutic option for 1alpha,25(OH)2D3-induced hypercalcemia.	25(oh)2d3	31-40	vitamin D receptor	Homo sapiens	133-136
31470109-6	2019	Upregulation of MMP-1 by UV was reversed by inhibition of 1alpha,25(OH)2D3 synthesis using ketoconazole or CYP27B1 siRNA.	25(oh)2d3	65-74	matrix metallopeptidase 1	Homo sapiens	16-21
32185608-4	2020	We have previously reported that Eldecalcitol (ED-71), an analog of 1alpha,25(OH)2D3, downregulated the expression of HBp17/FGFBP-1 and inhibited the proliferation of squamous cell carcinoma (SCC) cells in vitro and in vivo through NF-kappab inhibition.	25(oh)2d3	75-84	fibroblast growth factor binding protein 1	Homo sapiens	118-123
32185608-4	2020	We have previously reported that Eldecalcitol (ED-71), an analog of 1alpha,25(OH)2D3, downregulated the expression of HBp17/FGFBP-1 and inhibited the proliferation of squamous cell carcinoma (SCC) cells in vitro and in vivo through NF-kappab inhibition.	25(oh)2d3	75-84	fibroblast growth factor binding protein 1	Homo sapiens	124-131
32120344-6	2020	Of interest, we observed that 1alpha,25(OH)2D3 inhibits NF-kappaB activation and subsequent synthesis and secretion of IL-6 and IL-8 by promoting VDR and NF-kappaB p65 interaction.	25(oh)2d3	37-46	interleukin 6	Homo sapiens	119-123
32120344-6	2020	Of interest, we observed that 1alpha,25(OH)2D3 inhibits NF-kappaB activation and subsequent synthesis and secretion of IL-6 and IL-8 by promoting VDR and NF-kappaB p65 interaction.	25(oh)2d3	37-46	C-X-C motif chemokine ligand 8	Homo sapiens	128-132
32120344-6	2020	Of interest, we observed that 1alpha,25(OH)2D3 inhibits NF-kappaB activation and subsequent synthesis and secretion of IL-6 and IL-8 by promoting VDR and NF-kappaB p65 interaction.	25(oh)2d3	37-46	vitamin D receptor	Homo sapiens	146-149
32120344-6	2020	Of interest, we observed that 1alpha,25(OH)2D3 inhibits NF-kappaB activation and subsequent synthesis and secretion of IL-6 and IL-8 by promoting VDR and NF-kappaB p65 interaction.	25(oh)2d3	37-46	RELA proto-oncogene, NF-kB subunit	Homo sapiens	154-167
32120344-8	2020	These results suggest that 1alpha,25(OH)2D3 inhibits LPS-induced proliferation, migration and invasion in prostate cancer cells by directly and indirectly blocking STAT3 signal transduction.	25(oh)2d3	34-43	signal transducer and activator of transcription 3	Homo sapiens	164-169
31470109-13	2019	Moreover, UV irradiation upregulates the enzyme CYP27B1, which leads to 1alpha,25(OH)2D3 synthesis, but downregulates the cholesterol-producing enzyme DHCR7, both of which collectively lead to increased MMP-1 expression in human keratinocytes.	25(oh)2d3	79-88	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	48-55
31373168-2	2019	This study aimed to identify the substrate of PTPN2 in mediating beneficial effects of 25-Hydroxyvitamin D3 (25(OH)2D3 ) on diabetic periodontitis.	25(oh)2d3	109-118	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	46-51
31373168-5	2019	We identified PTPN2 as a direct target of 25(OH)2D3 , which effectively inhibited inflammation and bone resorption in diabetic periodontitis mice.	25(oh)2d3	42-51	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	14-19
31002352-4	2019	Furthermore, 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] treatment inhibited the self-renewal capacity of SP cells by decreasing the sphere formation rate and by suppressing the mRNA expression levels of cluster of differentiation CD44, NANOG, OCT4, SOX2, Kruppel-like factor 4 and adenosine triphosphate binding cassette subfamily G member 2.	25(oh)2d3	51-60	CD44 antigen	Mus musculus	236-240
30893561-6	2019	In addition, 1alpha,25(OH)2D3 biosynthesis was significantly lower in lo-Meg (46%, P = 0.034) and in si-Meg (23%, P < 0.001) than each control.	25(oh)2d3	20-29	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	73-76
30893561-6	2019	In addition, 1alpha,25(OH)2D3 biosynthesis was significantly lower in lo-Meg (46%, P = 0.034) and in si-Meg (23%, P < 0.001) than each control.	25(oh)2d3	20-29	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	104-107
31002352-4	2019	Furthermore, 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] treatment inhibited the self-renewal capacity of SP cells by decreasing the sphere formation rate and by suppressing the mRNA expression levels of cluster of differentiation CD44, NANOG, OCT4, SOX2, Kruppel-like factor 4 and adenosine triphosphate binding cassette subfamily G member 2.	25(oh)2d3	51-60	Nanog homeobox	Mus musculus	242-247
31002352-4	2019	Furthermore, 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] treatment inhibited the self-renewal capacity of SP cells by decreasing the sphere formation rate and by suppressing the mRNA expression levels of cluster of differentiation CD44, NANOG, OCT4, SOX2, Kruppel-like factor 4 and adenosine triphosphate binding cassette subfamily G member 2.	25(oh)2d3	51-60	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	249-253
31002352-4	2019	Furthermore, 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] treatment inhibited the self-renewal capacity of SP cells by decreasing the sphere formation rate and by suppressing the mRNA expression levels of cluster of differentiation CD44, NANOG, OCT4, SOX2, Kruppel-like factor 4 and adenosine triphosphate binding cassette subfamily G member 2.	25(oh)2d3	51-60	SRY (sex determining region Y)-box 2	Mus musculus	255-259
30690074-13	2019	Therefore, alpha-1-antitrypsin is required for 1,25(OH)2D3-induced IL-10 expression in CD4+ T cells, interacting with C3a to drive IL-10 expression.	25(oh)2d3	49-58	serpin family A member 1	Homo sapiens	11-30
30914204-2	2019	In this study, we investigated the effect and underlying mechanisms of HA accumulation on the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) induced by 1alpha,25(OH)2D3 and dexamethasone in stromal cells, which support osteoclastogenesis.	25(oh)2d3	186-195	TNF superfamily member 11	Homo sapiens	108-159
30914204-2	2019	In this study, we investigated the effect and underlying mechanisms of HA accumulation on the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) induced by 1alpha,25(OH)2D3 and dexamethasone in stromal cells, which support osteoclastogenesis.	25(oh)2d3	186-195	TNF superfamily member 11	Homo sapiens	161-166
30690074-13	2019	Therefore, alpha-1-antitrypsin is required for 1,25(OH)2D3-induced IL-10 expression in CD4+ T cells, interacting with C3a to drive IL-10 expression.	25(oh)2d3	49-58	interleukin 10	Homo sapiens	67-72
30690074-13	2019	Therefore, alpha-1-antitrypsin is required for 1,25(OH)2D3-induced IL-10 expression in CD4+ T cells, interacting with C3a to drive IL-10 expression.	25(oh)2d3	49-58	interleukin 10	Homo sapiens	131-136
29233620-6	2019	1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] acts through the vitamin D receptor (VDR) and a membrane associated receptor, protein disulfide isomerase A3 (PDIA3).	25(oh)2d3	38-47	protein disulfide isomerase family A member 3	Homo sapiens	127-157
30308321-3	2019	We have previously demonstrated that 1alpha,25(OH)2D3 induces apoptosis in a VDR dependent manner, inhibits vGPCR cell growth and NF-kappaB activity.	25(oh)2d3	44-53	vitamin D receptor	Homo sapiens	77-80
29233620-6	2019	1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] acts through the vitamin D receptor (VDR) and a membrane associated receptor, protein disulfide isomerase A3 (PDIA3).	25(oh)2d3	38-47	vitamin D receptor	Homo sapiens	66-84
29233620-6	2019	1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] acts through the vitamin D receptor (VDR) and a membrane associated receptor, protein disulfide isomerase A3 (PDIA3).	25(oh)2d3	38-47	vitamin D receptor	Homo sapiens	86-89
30481575-6	2019	Moreover, PFKFB4 inhibition in 1alpha,25(OH)2D3-treated DCs blocked their hallmark capacity to induce suppressive Tregs.	25(oh)2d3	38-47	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	Homo sapiens	10-16
29233620-6	2019	1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] acts through the vitamin D receptor (VDR) and a membrane associated receptor, protein disulfide isomerase A3 (PDIA3).	25(oh)2d3	38-47	protein disulfide isomerase family A member 3	Homo sapiens	159-164
30217510-9	2018	Activation of apical CaSR by cinacalcet and AC-265347 abolished 1,25(OH)2D3-induced calcium transport in a dose-dependent manner.	25(oh)2d3	66-75	calcium-sensing receptor	Rattus norvegicus	21-25
30697360-11	2019	Furthermore, 10 nM of 1alpha,25(OH)2D3 generally inhibited the IL-6 and IL-1beta-mediated inflammatory responses, and reduced both p44/42 MAPK and relA phosphorylation in MacCM-stimulated preadipocytes.	25(oh)2d3	29-38	interleukin 6	Homo sapiens	63-67
30697360-11	2019	Furthermore, 10 nM of 1alpha,25(OH)2D3 generally inhibited the IL-6 and IL-1beta-mediated inflammatory responses, and reduced both p44/42 MAPK and relA phosphorylation in MacCM-stimulated preadipocytes.	25(oh)2d3	29-38	interleukin 1 beta	Homo sapiens	72-80
30697360-11	2019	Furthermore, 10 nM of 1alpha,25(OH)2D3 generally inhibited the IL-6 and IL-1beta-mediated inflammatory responses, and reduced both p44/42 MAPK and relA phosphorylation in MacCM-stimulated preadipocytes.	25(oh)2d3	29-38	interferon induced protein 44	Homo sapiens	131-134
30697360-11	2019	Furthermore, 10 nM of 1alpha,25(OH)2D3 generally inhibited the IL-6 and IL-1beta-mediated inflammatory responses, and reduced both p44/42 MAPK and relA phosphorylation in MacCM-stimulated preadipocytes.	25(oh)2d3	29-38	RELA proto-oncogene, NF-kB subunit	Homo sapiens	147-151
30031146-9	2019	This suggests that another enzyme than Cyp27b1 is present for the 1,25(OH)2D3 synthesis.	25(oh)2d3	68-77	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	39-46
29964038-2	2018	1alpha,25(OH)2D3 vitamin D (the active form of vitamin D) induces transcription of the uridine phosphorylase gene (UPP1) in colon tissues of European Americans but to a lesser extent in colon tissues of African Americans.	25(oh)2d3	7-16	uridine phosphorylase 1	Mus musculus	115-119
28765038-12	2018	Twenty-four hour treatment with 1alpha,25(OH)2D3 (10nM) or E2 (10nM) upregulated each other"s receptor by as much as 5.8-fold for ERalpha and 2.9-fold for the VDR.	25(oh)2d3	39-48	estrogen receptor 1	Homo sapiens	130-143
29964038-10	2018	1alpha,25(OH)2D3 significantly reduced levels of uridine and uridine-induced DNA damage in these cells, which required UPP1 expression.	25(oh)2d3	7-16	uridine phosphorylase 1	Homo sapiens	119-123
29964038-11	2018	Organoids derived from colon tissues of African Americans expressed lower levels of UPP1 after exposure to 1alpha,25(OH)2D3 and had increased uridine-induced DNA damage compared with organoids derived from tissues of European Americans.	25(oh)2d3	114-123	uridine phosphorylase 1	Mus musculus	84-88
30010626-5	2018	FAM57B2 produced lactosylceramide (LacCer) upon specific binding of 24R,25(OH)2D3.	25(oh)2d3	72-81	TLC domain containing 3B	Mus musculus	0-6
29553126-3	2018	We evaluated the potential importance of 1,25(OH)2D3 in the diagnosis and treatment of papillary thyroid cancer (PTC).	25(oh)2d3	43-52	ret proto-oncogene	Homo sapiens	113-116
29553126-10	2018	RESULTS The preoperative serum level of 1,25(OH)2D3 in PTC was obviously lower than that in nodular goiter (NG) (P<0.05).	25(oh)2d3	42-51	ret proto-oncogene	Homo sapiens	55-58
28765038-12	2018	Twenty-four hour treatment with 1alpha,25(OH)2D3 (10nM) or E2 (10nM) upregulated each other"s receptor by as much as 5.8-fold for ERalpha and 2.9-fold for the VDR.	25(oh)2d3	39-48	vitamin D receptor	Homo sapiens	159-162
29196166-9	2018	Then the role of miR-204 and Tgfbr2 in the anti-PAH effect of 1,25(OH)2D3 was further explored by modulating the expression of the two genes.	25(oh)2d3	64-73	microRNA 204	Rattus norvegicus	17-24
29196166-9	2018	Then the role of miR-204 and Tgfbr2 in the anti-PAH effect of 1,25(OH)2D3 was further explored by modulating the expression of the two genes.	25(oh)2d3	64-73	transforming growth factor, beta receptor 2	Rattus norvegicus	29-35
29196166-10	2018	The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, alpha-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo.	25(oh)2d3	131-140	transforming growth factor, beta receptor 2	Rattus norvegicus	198-204
29196166-10	2018	The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, alpha-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo.	25(oh)2d3	131-140	actin gamma 2, smooth muscle	Rattus norvegicus	206-215
29196166-10	2018	The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, alpha-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo.	25(oh)2d3	131-140	SMAD family member 7	Rattus norvegicus	221-226
29196166-10	2018	The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, alpha-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo.	25(oh)2d3	131-140	microRNA 204	Rattus norvegicus	254-261
29196166-10	2018	The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, alpha-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo.	25(oh)2d3	131-140	KRAS proto-oncogene, GTPase	Rattus norvegicus	263-266
29196166-10	2018	The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, alpha-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo.	25(oh)2d3	131-140	SMAD family member 2	Rattus norvegicus	271-276
29999169-5	2018	The potential for reciprocal effects from 1alpha,25(OH)2D3 on megalin expression were also tested.	25(oh)2d3	49-58	LDL receptor related protein 2	Homo sapiens	62-69
27876536-16	2017	Our results showed a protective effect of 1alpha,25(OH)2D3 and metformin on liver in diabetic rats as indicated by an improvement of the level of the liver enzymes, decreased apoptosis and increased proliferation and this was confirmed histologically, with modulating NFkB and PPAR-alpha.	25(oh)2d3	49-58	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	268-272
29042442-4	2017	Here, using in vitro and in vivo approaches including osteoblast-specific, conditional FoxO1-knock-out mice, we demonstrate that 1,25(OH)2D3 ameliorates abnormal osteoblast proliferation in DM-induced oxidative stress conditions and rescues the impaired glucose and bone metabolism through FoxO1 nuclear exclusion resulting from the activation of PI3K/Akt signaling.	25(oh)2d3	131-140	forkhead box O1	Mus musculus	87-92
29042442-4	2017	Here, using in vitro and in vivo approaches including osteoblast-specific, conditional FoxO1-knock-out mice, we demonstrate that 1,25(OH)2D3 ameliorates abnormal osteoblast proliferation in DM-induced oxidative stress conditions and rescues the impaired glucose and bone metabolism through FoxO1 nuclear exclusion resulting from the activation of PI3K/Akt signaling.	25(oh)2d3	131-140	forkhead box O1	Mus musculus	290-295
29042442-4	2017	Here, using in vitro and in vivo approaches including osteoblast-specific, conditional FoxO1-knock-out mice, we demonstrate that 1,25(OH)2D3 ameliorates abnormal osteoblast proliferation in DM-induced oxidative stress conditions and rescues the impaired glucose and bone metabolism through FoxO1 nuclear exclusion resulting from the activation of PI3K/Akt signaling.	25(oh)2d3	131-140	thymoma viral proto-oncogene 1	Mus musculus	352-355
27876536-16	2017	Our results showed a protective effect of 1alpha,25(OH)2D3 and metformin on liver in diabetic rats as indicated by an improvement of the level of the liver enzymes, decreased apoptosis and increased proliferation and this was confirmed histologically, with modulating NFkB and PPAR-alpha.	25(oh)2d3	49-58	peroxisome proliferator activated receptor alpha	Rattus norvegicus	277-287
26956363-10	2016	These findings indicate that administration of 1alpha,25(OH)2D3 might provide a favorable microenvironment for orthodontic tooth movement by downregulating expression of HMGB1 in PDL cells.	25(oh)2d3	54-63	high mobility group box 1	Rattus norvegicus	170-175
28245293-9	2017	Western blot analysis demonstrated that the mTOR/STAT3/ERK pathway was downregulated by 1,25(OH)2D3 in HRPTEpiC.	25(oh)2d3	90-99	mechanistic target of rapamycin kinase	Homo sapiens	44-48
28245293-9	2017	Western blot analysis demonstrated that the mTOR/STAT3/ERK pathway was downregulated by 1,25(OH)2D3 in HRPTEpiC.	25(oh)2d3	90-99	signal transducer and activator of transcription 3	Homo sapiens	49-54
28245293-9	2017	Western blot analysis demonstrated that the mTOR/STAT3/ERK pathway was downregulated by 1,25(OH)2D3 in HRPTEpiC.	25(oh)2d3	90-99	mitogen-activated protein kinase 1	Homo sapiens	55-58
27382252-7	2016	In addition, 1alpha,25(OH)2D3 and MART-10 treatment inhibited intracellular MMP-9 expression and extracellular MMP activity in FaDu cells.	25(oh)2d3	20-29	matrix metallopeptidase 9	Homo sapiens	76-81
27382252-7	2016	In addition, 1alpha,25(OH)2D3 and MART-10 treatment inhibited intracellular MMP-9 expression and extracellular MMP activity in FaDu cells.	25(oh)2d3	20-29	matrix metallopeptidase 9	Homo sapiens	76-79
28218743-2	2017	Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1.	25(oh)2d3	130-139	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	65-71
28218743-2	2017	Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1.	25(oh)2d3	130-139	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	75-82
28218743-2	2017	Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1alpha-hydroxylase (CYP27B1) to produce 1,25(OH)2D3, or through the action of CYP11A1 to produce mono-di- and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1.	25(oh)2d3	130-139	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	108-115
28514663-8	2017	Our results demonstrate that regulation of 1alpha,25(OH)2D3 during lipid metabolism occurs through the regulation of Pgc1a for mitochondrial biogenesis and oxidative metabolism within zebrafish VAT.	25(oh)2d3	50-59	peroxisome proliferator-activated receptor gamma, coactivator 1 alpha	Danio rerio	117-122
27852823-5	2017	In HPK1ARas cells, 1alpha,25(OH)2D3-induced nuclear localization and interaction of hRXRalpha are restored when cells are treated with the MEK1/2 inhibitor UO126 or following transfection of the non-phosphorylatable hRXRalpha Ala-260 mutant.	25(oh)2d3	26-35	retinoid X receptor alpha	Homo sapiens	84-93
27852823-5	2017	In HPK1ARas cells, 1alpha,25(OH)2D3-induced nuclear localization and interaction of hRXRalpha are restored when cells are treated with the MEK1/2 inhibitor UO126 or following transfection of the non-phosphorylatable hRXRalpha Ala-260 mutant.	25(oh)2d3	26-35	mitogen-activated protein kinase kinase 1	Homo sapiens	139-145
27852823-5	2017	In HPK1ARas cells, 1alpha,25(OH)2D3-induced nuclear localization and interaction of hRXRalpha are restored when cells are treated with the MEK1/2 inhibitor UO126 or following transfection of the non-phosphorylatable hRXRalpha Ala-260 mutant.	25(oh)2d3	26-35	retinoid X receptor alpha	Homo sapiens	216-225
26704532-10	2016	Furthermore, CYP24A1 mRNA levels in NSC-34 cells were up-regulated by 1alpha,25(OH)2D3 and its synthetic analogs, EB1089 and tacalcitol.	25(oh)2d3	77-86	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	13-20
26878191-4	2016	Here, we report that treatment of UMR106 osteoblast-like cells with 1,25(OH)2D3, inducing Fgf23 transcription, resulted in actin polymerization which was blocked by NFkappaB inhibitor wogonin.	25(oh)2d3	70-79	fibroblast growth factor 23	Rattus norvegicus	90-95
26469137-5	2016	In addition, we show that 1alpha,25(OH)2D3 inhibits myoblast proliferation and differentiation by altering the expression of cell cycle regulators and myogenic regulatory factors, with associated changes in forkhead box O3 and Notch signaling pathways.	25(oh)2d3	33-42	forkhead box O3	Homo sapiens	207-222
26343586-10	2016	1alpha,25(OH)2D3 significantly counteracted the increased CTX-II release due to TNF-alpha stimulation, and this effect was significantly suppressed by SB505124.	25(oh)2d3	7-16	tumor necrosis factor	Rattus norvegicus	80-89
27997893-0	2016	1alpha,25(OH)2D3 Induces Actin Depolymerization in Endometrial Carcinoma Cells by Targeting RAC1 and PAK1.	25(oh)2d3	7-16	Rac family small GTPase 1	Homo sapiens	92-96
27997893-0	2016	1alpha,25(OH)2D3 Induces Actin Depolymerization in Endometrial Carcinoma Cells by Targeting RAC1 and PAK1.	25(oh)2d3	7-16	p21 (RAC1) activated kinase 1	Homo sapiens	101-105
23784946-9	2016	1alpha,25(OH)2D3 reduced mineral in WT and Sh-VDR cultures; BMP2 increased mineralization; and 1alpha,25(OH)2D3 + BMP2 caused a synergistic increase, but only in WT cultures.	25(oh)2d3	7-16	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	46-49
26385607-5	2016	In this study, we aimed to investigate the effect of MART-10 and 1alpha,25(OH)2D3 on angiogenesis in vitro and in vivo.	25(oh)2d3	72-81	septin 4	Homo sapiens	53-57
26254608-1	2015	We have previously shown that 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] and its less calcemic analog TX 527 induce apoptosis via caspase-3 activation in endothelial cells (SVEC) and endothelial cells transformed by the viral G protein-coupled receptor associated to Kaposi sarcoma (vGPCR).	25(oh)2d3	68-77	caspase 3	Homo sapiens	136-145
26827954-2	2016	This activity is commonly attributed to direct binding of 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3, calcitriol], the hormonally active form of vitamin D, to the vitamin D receptor (VDR).	25(oh)2d3	96-105	vitamin D receptor	Homo sapiens	168-186
26827954-2	2016	This activity is commonly attributed to direct binding of 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3, calcitriol], the hormonally active form of vitamin D, to the vitamin D receptor (VDR).	25(oh)2d3	96-105	vitamin D receptor	Homo sapiens	188-191
26523511-6	2015	TGF-beta1/beta2-induced increased expression of EMT-related transcription factors was also inhibited by 1,25(OH)2D3.	25(oh)2d3	106-115	transforming growth factor beta 1	Homo sapiens	0-9
26523511-6	2015	TGF-beta1/beta2-induced increased expression of EMT-related transcription factors was also inhibited by 1,25(OH)2D3.	25(oh)2d3	106-115	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	10-15
26025591-8	2015	The presence of vitamin D receptor (VDR) and the enzyme responsible for conversion of the 25(OH)D in its active metabolite 25(OH)2D3 in extra renal tissue shows the involvement of vitamin D in other diseases like cancer, diabetes, multiple sclerosis etc.	25(oh)2d3	123-132	vitamin D receptor	Homo sapiens	16-34
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	protein disulfide isomerase family A member 3	Homo sapiens	28-33
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	protein disulfide isomerase family A member 3	Homo sapiens	67-72
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	phospholipase A2 group IB	Homo sapiens	77-93
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	phospholipase A2 group IB	Homo sapiens	95-99
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	phospholipase A2 activating protein	Homo sapiens	121-125
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	214-220
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	phospholipase A2 group IB	Homo sapiens	223-227
25845934-3	2015	1alpha,25(OH)2D3 binding to Pdia3 triggers the interaction between Pdia3 and phospholipase A2 (PLA2)-activating protein (PLAA), resulting in downstream activation of calcium/calmodulin-dependent protein kinase II (CaMKII), PLA2, and protein kinase C (PKC).	25(oh)2d3	7-16	proline rich transmembrane protein 2	Homo sapiens	251-254
26025591-8	2015	The presence of vitamin D receptor (VDR) and the enzyme responsible for conversion of the 25(OH)D in its active metabolite 25(OH)2D3 in extra renal tissue shows the involvement of vitamin D in other diseases like cancer, diabetes, multiple sclerosis etc.	25(oh)2d3	123-132	vitamin D receptor	Homo sapiens	36-39
26029210-5	2015	Importantly, we found that the hormonally active form of vitamin D 1,25(OH)2D3 not only prevents the UVR-induced small HA activation of abnormal keratinocyte behavior and SCC progression, but also enhances large HA stimulation of normal keratinocyte activities and epidermal function(s).	25(oh)2d3	69-78	histidine ammonia-lyase	Homo sapiens	119-121
26124321-3	2015	The aim of the present study was to elucidate the role of 1alpha,25(OH)2D3 production by 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) on prostate cancer cell growth.	25(oh)2d3	65-74	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	129-136
26062551-5	2015	Treatment of HDPCs with 1alpha,25(OH)2D3 at a concentration of 10 nM or 100 nM significantly upregulated the expression of dentin sialophosphoprotein (DSPP) and dentin matrix protein1 (DMP1), the odontogenesis-related genes.	25(oh)2d3	31-40	dentin sialophosphoprotein	Homo sapiens	123-149
26062551-5	2015	Treatment of HDPCs with 1alpha,25(OH)2D3 at a concentration of 10 nM or 100 nM significantly upregulated the expression of dentin sialophosphoprotein (DSPP) and dentin matrix protein1 (DMP1), the odontogenesis-related genes.	25(oh)2d3	31-40	dentin sialophosphoprotein	Homo sapiens	151-155
26062551-5	2015	Treatment of HDPCs with 1alpha,25(OH)2D3 at a concentration of 10 nM or 100 nM significantly upregulated the expression of dentin sialophosphoprotein (DSPP) and dentin matrix protein1 (DMP1), the odontogenesis-related genes.	25(oh)2d3	31-40	dentin matrix acidic phosphoprotein 1	Homo sapiens	161-183
26062551-5	2015	Treatment of HDPCs with 1alpha,25(OH)2D3 at a concentration of 10 nM or 100 nM significantly upregulated the expression of dentin sialophosphoprotein (DSPP) and dentin matrix protein1 (DMP1), the odontogenesis-related genes.	25(oh)2d3	31-40	dentin matrix acidic phosphoprotein 1	Homo sapiens	185-189
26062551-8	2015	These results demonstrated that 1alpha,25(OH)2D3 promoted odontoblastic differentiation of HDPCs via modulating ERK activation.	25(oh)2d3	39-48	mitogen-activated protein kinase 1	Homo sapiens	112-115
26029210-5	2015	Importantly, we found that the hormonally active form of vitamin D 1,25(OH)2D3 not only prevents the UVR-induced small HA activation of abnormal keratinocyte behavior and SCC progression, but also enhances large HA stimulation of normal keratinocyte activities and epidermal function(s).	25(oh)2d3	69-78	serpin family B member 3	Homo sapiens	171-174
26029210-5	2015	Importantly, we found that the hormonally active form of vitamin D 1,25(OH)2D3 not only prevents the UVR-induced small HA activation of abnormal keratinocyte behavior and SCC progression, but also enhances large HA stimulation of normal keratinocyte activities and epidermal function(s).	25(oh)2d3	69-78	histidine ammonia-lyase	Homo sapiens	212-214
25448737-2	2015	In its membrane-initiated pathway, after 1alpha,25(OH)2D3 interacts with protein disulfide isomerase, family A, member 3 (Pdia3) in caveolae, phospholipase A2 (PLA2) and protein kinase C (PKC) are activated.	25(oh)2d3	48-57	protein disulfide isomerase family A member 3	Homo sapiens	73-120
26191332-1	2015	1alpha, 25-dihydroxyvitamin D3 (1alpha, 25(OH)2D3) acts on the osteoblasts to enhance the expressions of receptor activator of nuclear factor kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) and induce the formation of osteoclasts.	25(oh)2d3	40-49	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	105-155
26191332-1	2015	1alpha, 25-dihydroxyvitamin D3 (1alpha, 25(OH)2D3) acts on the osteoblasts to enhance the expressions of receptor activator of nuclear factor kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) and induce the formation of osteoclasts.	25(oh)2d3	40-49	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	157-162
26191332-1	2015	1alpha, 25-dihydroxyvitamin D3 (1alpha, 25(OH)2D3) acts on the osteoblasts to enhance the expressions of receptor activator of nuclear factor kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) and induce the formation of osteoclasts.	25(oh)2d3	40-49	colony stimulating factor 1 (macrophage)	Mus musculus	168-204
26191332-1	2015	1alpha, 25-dihydroxyvitamin D3 (1alpha, 25(OH)2D3) acts on the osteoblasts to enhance the expressions of receptor activator of nuclear factor kappaB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) and induce the formation of osteoclasts.	25(oh)2d3	40-49	colony stimulating factor 1 (macrophage)	Mus musculus	206-211
26191332-9	2015	Taken together, our data indicated that osteoblastic NF-kappaB pathway was involved in 1alpha, 25(OH)2D3-induced osteoclast-like cells formation from BMMNCs through regulating the expression of RANKL and M-CSF.	25(oh)2d3	95-104	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	194-199
26191332-9	2015	Taken together, our data indicated that osteoblastic NF-kappaB pathway was involved in 1alpha, 25(OH)2D3-induced osteoclast-like cells formation from BMMNCs through regulating the expression of RANKL and M-CSF.	25(oh)2d3	95-104	colony stimulating factor 1 (macrophage)	Mus musculus	204-209
25614971-0	2015	High glucose upregulates CYP24A1 expression which attenuates the ability of 1,25(OH)2D3 to increase NGF secretion in a rat Schwann cell line RSC96.	25(oh)2d3	78-87	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	25-32
25614971-0	2015	High glucose upregulates CYP24A1 expression which attenuates the ability of 1,25(OH)2D3 to increase NGF secretion in a rat Schwann cell line RSC96.	25(oh)2d3	78-87	nerve growth factor	Rattus norvegicus	100-103
25448737-2	2015	In its membrane-initiated pathway, after 1alpha,25(OH)2D3 interacts with protein disulfide isomerase, family A, member 3 (Pdia3) in caveolae, phospholipase A2 (PLA2) and protein kinase C (PKC) are activated.	25(oh)2d3	48-57	protein disulfide isomerase family A member 3	Homo sapiens	122-127
25448737-2	2015	In its membrane-initiated pathway, after 1alpha,25(OH)2D3 interacts with protein disulfide isomerase, family A, member 3 (Pdia3) in caveolae, phospholipase A2 (PLA2) and protein kinase C (PKC) are activated.	25(oh)2d3	48-57	phospholipase A2 group IB	Homo sapiens	142-158
25448737-2	2015	In its membrane-initiated pathway, after 1alpha,25(OH)2D3 interacts with protein disulfide isomerase, family A, member 3 (Pdia3) in caveolae, phospholipase A2 (PLA2) and protein kinase C (PKC) are activated.	25(oh)2d3	48-57	phospholipase A2 group IB	Homo sapiens	160-164
25327179-2	2015	We tested the hypothesis that increasing 1,25(OH)2D3 synthesis locally by targeting delivery of the 1alpha-hydroxylase gene (CYP27B1) to the inflamed bowel would ameliorate IBD without causing hypercalcemia.	25(oh)2d3	43-52	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	125-132
25876656-7	2015	Thus, this study showed that 1alpha,25(OH)2D3 might have an inhibitory effect on the expression of MAFbx and MuRF1 in skeletal muscle and a suppressive effect on muscle degradation in patients with osteoporosis.	25(oh)2d3	36-45	tripartite motif containing 63	Homo sapiens	109-114
25405762-2	2014	Protein disulfide isomerase family A, member 3 (PDIA3) mediates 1alpha,25(OH)2D3 initiated-rapid membrane signaling in several cell types.	25(oh)2d3	71-80	protein disulfide isomerase associated 3	Mus musculus	0-46
25263660-5	2015	The aim of the present study is to evaluate the roles of CaM and CaMKII as mediators of 1alpha,25(OH)2D3-stimulated PLAA-dependent activation of cPLA2 and PKCalpha, and downstream biological effects.	25(oh)2d3	95-104	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	65-71
25263660-5	2015	The aim of the present study is to evaluate the roles of CaM and CaMKII as mediators of 1alpha,25(OH)2D3-stimulated PLAA-dependent activation of cPLA2 and PKCalpha, and downstream biological effects.	25(oh)2d3	95-104	phospholipase A2 activating protein	Homo sapiens	116-120
25263660-5	2015	The aim of the present study is to evaluate the roles of CaM and CaMKII as mediators of 1alpha,25(OH)2D3-stimulated PLAA-dependent activation of cPLA2 and PKCalpha, and downstream biological effects.	25(oh)2d3	95-104	phospholipase A2 group IVA	Homo sapiens	145-150
25263660-5	2015	The aim of the present study is to evaluate the roles of CaM and CaMKII as mediators of 1alpha,25(OH)2D3-stimulated PLAA-dependent activation of cPLA2 and PKCalpha, and downstream biological effects.	25(oh)2d3	95-104	protein kinase C alpha	Homo sapiens	155-163
25149065-3	2014	Previously we have shown that vitamin D analog, MART-10 (19-nor-2alpha-(3-hydroxypropyl)-1alpha,25(OH)2D3), exerted potent antiproliferative effect on PDA in vitro and in vivo without causing hypercalcemia.	25(oh)2d3	96-105	septin 4	Homo sapiens	48-52
25149065-6	2014	1alpha,25(OH)2D3 and MART-10 inhibited epithelial-mesenchymal transition (EMT) in pancreatic cancer cells through downregulation of Snail, Slug, and Vimentin expression in BxPC-3 and PANC cells.	25(oh)2d3	7-16	snail family transcriptional repressor 1	Homo sapiens	132-137
25876656-4	2015	Myotubes treated with 1alpha,25(OH)2D3 increased interleukin-6 (IL-6) expression and inhibited expression of tumor necrosis factor alpha (TNF-alpha), whereas the expression of insulin-like growth factor-1 (IGF-1) that is involved in muscle hypertrophy was not affected.	25(oh)2d3	29-38	interleukin 6	Homo sapiens	49-62
25876656-4	2015	Myotubes treated with 1alpha,25(OH)2D3 increased interleukin-6 (IL-6) expression and inhibited expression of tumor necrosis factor alpha (TNF-alpha), whereas the expression of insulin-like growth factor-1 (IGF-1) that is involved in muscle hypertrophy was not affected.	25(oh)2d3	29-38	interleukin 6	Homo sapiens	64-68
25876656-4	2015	Myotubes treated with 1alpha,25(OH)2D3 increased interleukin-6 (IL-6) expression and inhibited expression of tumor necrosis factor alpha (TNF-alpha), whereas the expression of insulin-like growth factor-1 (IGF-1) that is involved in muscle hypertrophy was not affected.	25(oh)2d3	29-38	tumor necrosis factor	Homo sapiens	109-136
25876656-4	2015	Myotubes treated with 1alpha,25(OH)2D3 increased interleukin-6 (IL-6) expression and inhibited expression of tumor necrosis factor alpha (TNF-alpha), whereas the expression of insulin-like growth factor-1 (IGF-1) that is involved in muscle hypertrophy was not affected.	25(oh)2d3	29-38	tumor necrosis factor	Homo sapiens	138-147
25876656-4	2015	Myotubes treated with 1alpha,25(OH)2D3 increased interleukin-6 (IL-6) expression and inhibited expression of tumor necrosis factor alpha (TNF-alpha), whereas the expression of insulin-like growth factor-1 (IGF-1) that is involved in muscle hypertrophy was not affected.	25(oh)2d3	29-38	insulin like growth factor 1	Homo sapiens	206-211
25876656-5	2015	However, 1alpha,25(OH)2D3 treatment significantly inhibited the expression of muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MuRF1), ubiquitin ligases involved in muscle atrophy.	25(oh)2d3	16-25	F-box protein 32	Homo sapiens	100-105
25876656-5	2015	However, 1alpha,25(OH)2D3 treatment significantly inhibited the expression of muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MuRF1), ubiquitin ligases involved in muscle atrophy.	25(oh)2d3	16-25	tripartite motif containing 63	Homo sapiens	133-138
25876656-7	2015	Thus, this study showed that 1alpha,25(OH)2D3 might have an inhibitory effect on the expression of MAFbx and MuRF1 in skeletal muscle and a suppressive effect on muscle degradation in patients with osteoporosis.	25(oh)2d3	36-45	F-box protein 32	Homo sapiens	99-104
25263660-2	2015	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating cytosolic PLA2 and resulting in prostaglandin E2 (PGE2) release and PKCalpha activation, subsequently stimulating differentiation.	25(oh)2d3	7-16	protein disulfide isomerase family A member 3	Homo sapiens	28-33
25263660-2	2015	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating cytosolic PLA2 and resulting in prostaglandin E2 (PGE2) release and PKCalpha activation, subsequently stimulating differentiation.	25(oh)2d3	7-16	phospholipase A2 group IB	Homo sapiens	43-59
25263660-2	2015	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating cytosolic PLA2 and resulting in prostaglandin E2 (PGE2) release and PKCalpha activation, subsequently stimulating differentiation.	25(oh)2d3	7-16	phospholipase A2 group IB	Homo sapiens	61-65
25263660-2	2015	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating cytosolic PLA2 and resulting in prostaglandin E2 (PGE2) release and PKCalpha activation, subsequently stimulating differentiation.	25(oh)2d3	7-16	phospholipase A2 activating protein	Homo sapiens	87-91
25263660-2	2015	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating cytosolic PLA2 and resulting in prostaglandin E2 (PGE2) release and PKCalpha activation, subsequently stimulating differentiation.	25(oh)2d3	7-16	phospholipase A2 group IB	Homo sapiens	127-131
25263660-2	2015	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating cytosolic PLA2 and resulting in prostaglandin E2 (PGE2) release and PKCalpha activation, subsequently stimulating differentiation.	25(oh)2d3	7-16	protein kinase C alpha	Homo sapiens	185-193
26684854-1	2015	BACKGROUND/AIMS: Klotho, a transmembrane protein expressed in chorioid plexus of the brain, kidney, and several other tissues, is required for inhibition of 1,25(OH)2D3 formation by FGF23.	25(oh)2d3	159-168	fibroblast growth factor 23, gene 2 S homeolog	Xenopus laevis	182-187
26290720-0	2014	Influence of 1alpha, 25-dihydroxyvitamin D3 [1, 25(OH)2D3] on the expression of Sox 9 and the transient receptor potential vanilloid 5/6 ion channels in equine articular chondrocytes.	25(oh)2d3	48-57	SRY-box transcription factor 9	Equus caballus	80-85
25405762-2	2014	Protein disulfide isomerase family A, member 3 (PDIA3) mediates 1alpha,25(OH)2D3 initiated-rapid membrane signaling in several cell types.	25(oh)2d3	71-80	protein disulfide isomerase associated 3	Mus musculus	48-53
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	51-60	Wnt family member 5A	Homo sapiens	13-18
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	51-60	proline rich transmembrane protein 2	Homo sapiens	72-75
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	51-60	Wnt family member 5A	Homo sapiens	96-101
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	51-60	Wnt family member 5A	Homo sapiens	96-101
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	137-146	Wnt family member 5A	Homo sapiens	13-18
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	137-146	Wnt family member 5A	Homo sapiens	96-101
24946135-9	2014	In contrast, Wnt5a had a biphasic effect on 1alpha,25(OH)2D3-stimulated PKC activation; 50ng/ml Wnt5a caused a 2-fold increase in 1alpha,25(OH)2D3-stimulated PKC but higher Wnt5a concentrations reduced 1alpha,25(OH)2D3-stimulated PKC activation.	25(oh)2d3	137-146	Wnt family member 5A	Homo sapiens	96-101
24938357-0	2014	1alpha,25(OH)2D3 inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1.	25(oh)2d3	7-16	fibroblast growth factor 2	Homo sapiens	26-31
25147982-5	2014	In the present study, we introduced into VDR-null mice a human VDR (hVDR) bacterial artificial chromosome minigene containing a mutation that converts leucine to serine at amino acid 233 in the hVDR protein, which prevents 1,25(OH)2D3 binding.	25(oh)2d3	225-234	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	41-44
25147982-5	2014	In the present study, we introduced into VDR-null mice a human VDR (hVDR) bacterial artificial chromosome minigene containing a mutation that converts leucine to serine at amino acid 233 in the hVDR protein, which prevents 1,25(OH)2D3 binding.	25(oh)2d3	225-234	vitamin D receptor	Homo sapiens	63-66
25147982-5	2014	In the present study, we introduced into VDR-null mice a human VDR (hVDR) bacterial artificial chromosome minigene containing a mutation that converts leucine to serine at amino acid 233 in the hVDR protein, which prevents 1,25(OH)2D3 binding.	25(oh)2d3	225-234	vitamin D receptor	Homo sapiens	68-72
25147982-5	2014	In the present study, we introduced into VDR-null mice a human VDR (hVDR) bacterial artificial chromosome minigene containing a mutation that converts leucine to serine at amino acid 233 in the hVDR protein, which prevents 1,25(OH)2D3 binding.	25(oh)2d3	225-234	vitamin D receptor	Homo sapiens	194-198
24938357-0	2014	1alpha,25(OH)2D3 inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1.	25(oh)2d3	7-16	fibroblast growth factor binding protein 1	Homo sapiens	107-112
24938357-0	2014	1alpha,25(OH)2D3 inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1.	25(oh)2d3	7-16	fibroblast growth factor binding protein 1	Homo sapiens	113-120
24461581-3	2014	OBJECTIVE: We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity.	25(oh)2d3	84-93	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	199-206
24291401-1	2014	Calcitriol (1alpha,25-dihydroxyvitamin D3, 1alpha,25(OH)2D3) is an essential hormone that works in cooperation with parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) to regulate calcium and phosphorus homeostasis.	25(oh)2d3	50-59	parathyroid hormone	Rattus norvegicus	116-135
24291401-1	2014	Calcitriol (1alpha,25-dihydroxyvitamin D3, 1alpha,25(OH)2D3) is an essential hormone that works in cooperation with parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) to regulate calcium and phosphorus homeostasis.	25(oh)2d3	50-59	parathyroid hormone	Rattus norvegicus	137-140
24291401-1	2014	Calcitriol (1alpha,25-dihydroxyvitamin D3, 1alpha,25(OH)2D3) is an essential hormone that works in cooperation with parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) to regulate calcium and phosphorus homeostasis.	25(oh)2d3	50-59	fibroblast growth factor 23	Rattus norvegicus	146-173
24291401-1	2014	Calcitriol (1alpha,25-dihydroxyvitamin D3, 1alpha,25(OH)2D3) is an essential hormone that works in cooperation with parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) to regulate calcium and phosphorus homeostasis.	25(oh)2d3	50-59	fibroblast growth factor 23	Rattus norvegicus	175-181
24535953-10	2014	We now propose that the low potency of the intrinsic VDR-mediated activities of 25(OH)D3 can be augmented to the level of 1alpha,25(OH)2D3 without its activation through 1alpha-hydroxylation by CYP27B1, but by simply preventing its inactivation by CYP24A1.	25(oh)2d3	129-138	vitamin D receptor	Homo sapiens	53-56
25158196-3	2014	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating PLA2, resulting in prostaglandin E2 (PGE2) release and protein kinase C activation.	25(oh)2d3	7-16	protein disulfide isomerase family A, member 3	Rattus norvegicus	28-33
25158196-3	2014	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating PLA2, resulting in prostaglandin E2 (PGE2) release and protein kinase C activation.	25(oh)2d3	7-16	phospholipase A2 group IB	Rattus norvegicus	43-59
25158196-3	2014	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating PLA2, resulting in prostaglandin E2 (PGE2) release and protein kinase C activation.	25(oh)2d3	7-16	phospholipase A2 group IB	Rattus norvegicus	61-65
25158196-3	2014	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating PLA2, resulting in prostaglandin E2 (PGE2) release and protein kinase C activation.	25(oh)2d3	7-16	phospholipase A2, activating protein	Rattus norvegicus	87-91
25158196-3	2014	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating PLA2, resulting in prostaglandin E2 (PGE2) release and protein kinase C activation.	25(oh)2d3	7-16	phospholipase A2 group IB	Rattus norvegicus	117-121
25158196-3	2014	1alpha,25(OH)2D3 binding to Pdia3 leads to phospholipase-A2 (PLA2)-activating protein (PLAA) activation, stimulating PLA2, resulting in prostaglandin E2 (PGE2) release and protein kinase C activation.	25(oh)2d3	7-16	dihydrolipoamide S-succinyltransferase	Rattus norvegicus	150-167
25158196-11	2014	The results indicated that Pdia3, PLAA and caveolae are required for rapid 1alpha,25(OH)2D3 membrane-mediated activation of CaMKII.	25(oh)2d3	82-91	protein disulfide isomerase family A, member 3	Rattus norvegicus	27-32
25158196-11	2014	The results indicated that Pdia3, PLAA and caveolae are required for rapid 1alpha,25(OH)2D3 membrane-mediated activation of CaMKII.	25(oh)2d3	82-91	phospholipase A2, activating protein	Rattus norvegicus	34-38
25158196-12	2014	1alpha,25(OH)2D3 signaling via Pdia3 receptor triggered the interaction between PLAA and CaM suggesting that CaM may play a major role linking PLAA to CaMKII in membrane-mediated actions of 1alpha,25(OH)2D3.	25(oh)2d3	7-16	protein disulfide isomerase family A, member 3	Rattus norvegicus	31-36
25158196-12	2014	1alpha,25(OH)2D3 signaling via Pdia3 receptor triggered the interaction between PLAA and CaM suggesting that CaM may play a major role linking PLAA to CaMKII in membrane-mediated actions of 1alpha,25(OH)2D3.	25(oh)2d3	7-16	phospholipase A2, activating protein	Rattus norvegicus	80-84
25158196-12	2014	1alpha,25(OH)2D3 signaling via Pdia3 receptor triggered the interaction between PLAA and CaM suggesting that CaM may play a major role linking PLAA to CaMKII in membrane-mediated actions of 1alpha,25(OH)2D3.	25(oh)2d3	7-16	phospholipase A2, activating protein	Rattus norvegicus	143-147
24461581-3	2014	OBJECTIVE: We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity.	25(oh)2d3	84-93	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	222-225
24461581-5	2014	RESULTS: Here we show that mouse and human mast cells can convert 25OHD3 to 1alpha,25(OH)2D3 through CYP27B1 activity and that both of these vitamin D3 metabolites suppressed IgE-induced mast cell-derived proinflammatory and vasodilatory mediator production in a VDR-dependent manner in vitro.	25(oh)2d3	83-92	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	101-108
24587317-4	2014	The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament.	25(oh)2d3	145-154	interleukin 6	Mus musculus	176-189
24486455-4	2014	The purpose of the present study was to investigate the potential of ginsenosides and their aglycones to block hepatic and intestinal inactivation of 1alpha,25(OH)2D3, which is the most potent ligand of vitamin D receptor.	25(oh)2d3	157-166	vitamin D receptor	Homo sapiens	203-221
24597546-4	2014	24R,25(OH)2D3 inhibited hMSC proliferation, decreased 1alpha-hydroxylase (CYP27B) expression, thereby reducing the ability of hMSCs to convert 25(OH)D3 to 1alpha,25(OH)2D3, and promoted osteoblastic differentiation through increased alkaline phosphatase activity and Ca(2+) mineralization.	25(oh)2d3	4-13	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	74-80
24486455-7	2014	Co-incubation of 1alpha,25(OH)2D3 with various ginsenosides (Rg1, Rh2, aPPD, aPPT and total ginsenosides) led to differential inhibition (30-100%) of its hydroxylation.	25(oh)2d3	24-33	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	61-64
24486455-7	2014	Co-incubation of 1alpha,25(OH)2D3 with various ginsenosides (Rg1, Rh2, aPPD, aPPT and total ginsenosides) led to differential inhibition (30-100%) of its hydroxylation.	25(oh)2d3	24-33	Rh associated glycoprotein	Homo sapiens	66-69
24616223-4	2014	Overexpression of KLF4 in osteoblasts attenuated 1,25(OH)2D3-induced osteoclast differentiation in co-culture of mouse bone marrow cells and osteoblasts through the down-regulation of receptor activator of nuclear factor kappaB ligand (RANKL) expression.	25(oh)2d3	51-60	Kruppel-like factor 4 (gut)	Mus musculus	18-22
24587317-4	2014	The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament.	25(oh)2d3	145-154	interleukin 6	Mus musculus	191-195
24587317-4	2014	The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament.	25(oh)2d3	145-154	chemokine (C-X-C motif) ligand 15	Mus musculus	198-211
24291609-4	2014	The effects of the cell-derived 1alpha,25(OH)2D3 on vitamin D3 24-hydroxylase (CYP24A1) mRNA level and the cell growth inhibition were significantly lower than the effects of 25(OH)D3 itself added to cell culture.	25(oh)2d3	39-48	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	52-77
23747333-6	2013	Moreover, FGF-23 affected the 1,25(OH)2D3-induced change in duodenal water permeability as determined by tritiated water, but both 1,25(OH)2D3 and FGF-23 were without effects on the transepithelial fluxes of paracellular markers, (3)H-mannitol and (14)C-polyethylene glycol.	25(oh)2d3	32-41	fibroblast growth factor 23	Mus musculus	10-16
23869778-1	2014	The expression of CYP27B1 or vitamin D 1alpha-hydroxylase (1alpha-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1alpha,25-dihydroxyvitamin D [1alpha,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions.	25(oh)2d3	250-259	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	18-25
23869778-1	2014	The expression of CYP27B1 or vitamin D 1alpha-hydroxylase (1alpha-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1alpha,25-dihydroxyvitamin D [1alpha,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions.	25(oh)2d3	250-259	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	77-84
24044969-6	2013	A new class of less-calcemic 1alpha,25(OH)2D3 analog, MART-10 (19-nor-2alpha-(3-hydroxypropyl)- 1alpha,25-Dihydroxyvitamin D3), has been shown to be much more potent than 1alpha,25(OH)2D3 in inhibiting cancer cell growth in vitro and in vivo without inducing hypercalcemia.	25(oh)2d3	36-45	septin 4	Homo sapiens	54-58
24044969-6	2013	A new class of less-calcemic 1alpha,25(OH)2D3 analog, MART-10 (19-nor-2alpha-(3-hydroxypropyl)- 1alpha,25-Dihydroxyvitamin D3), has been shown to be much more potent than 1alpha,25(OH)2D3 in inhibiting cancer cell growth in vitro and in vivo without inducing hypercalcemia.	25(oh)2d3	178-187	septin 4	Homo sapiens	54-58
23606409-5	2013	For the first time, these studies resulted in the isolation and identification of 3-epi-calcitroic acid as the final inactive metabolite of 3-epi-1alpha,25(OH)2D3 produced by rat CYP24A1.	25(oh)2d3	153-162	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	179-186
24291609-4	2014	The effects of the cell-derived 1alpha,25(OH)2D3 on vitamin D3 24-hydroxylase (CYP24A1) mRNA level and the cell growth inhibition were significantly lower than the effects of 25(OH)D3 itself added to cell culture.	25(oh)2d3	39-48	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	79-86
23606409-9	2013	Docking results suggest that 3-epi-1alpha,25(OH)2D3, unlike 1alpha,25(OH)2D3, binds to CYP24A1 in an alternate configuration that destabilizes the formation of the enzyme-substrate complex sufficiently to slow the rate at which 3-epi-1alpha,25(OH)2D3 is inactivated by CYP24A1 through its metabolism into 3-epi-calcitroic acid.	25(oh)2d3	42-51	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	87-94
23606409-9	2013	Docking results suggest that 3-epi-1alpha,25(OH)2D3, unlike 1alpha,25(OH)2D3, binds to CYP24A1 in an alternate configuration that destabilizes the formation of the enzyme-substrate complex sufficiently to slow the rate at which 3-epi-1alpha,25(OH)2D3 is inactivated by CYP24A1 through its metabolism into 3-epi-calcitroic acid.	25(oh)2d3	42-51	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	269-276
23814095-9	2013	MAIN RESULTS AND THE ROLE OF CHANCE: 1-1000 nM 1,25(OH)2D3 significantly reduced mRNA levels of MMP-2 and MMP-9 in HuLM cells in a concentration-dependent manner (P < 0.5 to P < 0.001).	25(oh)2d3	49-58	matrix metallopeptidase 2	Homo sapiens	96-101
23814095-9	2013	MAIN RESULTS AND THE ROLE OF CHANCE: 1-1000 nM 1,25(OH)2D3 significantly reduced mRNA levels of MMP-2 and MMP-9 in HuLM cells in a concentration-dependent manner (P < 0.5 to P < 0.001).	25(oh)2d3	49-58	matrix metallopeptidase 9	Homo sapiens	106-111
23683514-10	2013	An antagonist of the ectonucleotidase CD39 reversed 1,25(OH)2D3-mediated inhibition of the IL-17A response.	25(oh)2d3	54-63	interleukin 17A	Homo sapiens	91-97
23782207-2	2013	Both 25(OH)vitamin D and 1alpha,25(OH)2D3 are difficult to analyse because of their lipophilic nature, affinity for VDBP and small concentrations.	25(oh)2d3	32-41	GC vitamin D binding protein	Homo sapiens	116-120
24312856-3	2013	In this study, Various stimuli [Dimethyl Sulfoxide (DMSO), active 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and LPS], either alone or in combination, have been recognized that have an effect on the level of CD14 expression in the human HL-60 and U937 promonocytic cell lines and therefore induce their terminal differentiation into monocytes or mature macrophages.	25(oh)2d3	94-103	CD14 molecule	Homo sapiens	204-208
23059474-6	2013	The over expression of CYP24A1 in cancer cells may be a factor affecting 1,25(OH)2D3 bioavailability and anti-proliferative activity pre-clinically and clinically.	25(oh)2d3	75-84	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	23-30
23660595-7	2013	Cells overexpressing Pdia3 with K214A and C406S mutations had PKC activity comparable to untreated controls, indicating that the native response to 1alpha,25(OH)2D3 also was blocked.	25(oh)2d3	155-164	protein disulfide isomerase associated 3	Mus musculus	21-26
23660595-9	2013	In contrast, 1alpha,25(OH)2D3 increased prostaglandin E2 in Pdia3[+-KDEL] cells.	25(oh)2d3	20-29	protein disulfide isomerase associated 3	Mus musculus	60-65
23683514-10	2013	An antagonist of the ectonucleotidase CD39 reversed 1,25(OH)2D3-mediated inhibition of the IL-17A response.	25(oh)2d3	54-63	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	38-42
23620751-9	2013	Bisulfite DNA pyrosequencing reveals 1,25(OH)2D3 to completely hypermethylate a single CpG site in the same BMP2 promoter region identified by the ChIP and reporter gene assays.	25(oh)2d3	39-48	bone morphogenetic protein 2	Rattus norvegicus	108-112
20307664-5	2010	VDR mRNA expression was detected in all samples and CYP24A1 mRNA expression was induced by 1alpha,25(OH)2D3 in both concentrations (but mainly with 100 nM).	25(oh)2d3	98-107	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	52-59
20619365-8	2011	1alpha,25(OH)2D3 levels are short-lived: the hormone upregulates its rapid metabolism by CYP24A1 that attacks repeatedly the vitamin D C20-27 side chain, thereby producing a complex cascade of transient metabolites with increasing polarity.	25(oh)2d3	7-16	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	89-96
20619365-9	2011	Most of these metabolites still retain 1alpha,25(OH)2D3-like activities on the VDR, contributing to the overall effect that is commonly attributed to 1alpha,25(OH)2D3.	25(oh)2d3	46-55	vitamin D receptor	Homo sapiens	79-82
20619365-9	2011	Most of these metabolites still retain 1alpha,25(OH)2D3-like activities on the VDR, contributing to the overall effect that is commonly attributed to 1alpha,25(OH)2D3.	25(oh)2d3	157-166	vitamin D receptor	Homo sapiens	79-82
20132886-4	2010	Correspondingly, CD578, WU515 and WY1113 are more potent inhibitors of beta-catenin/TCF signaling than 1,25(OH)2D3 and induce stronger VDR-coactivator interactions.	25(oh)2d3	105-114	catenin beta 1	Homo sapiens	71-83
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	25(oh)2d3	93-102	TNF receptor superfamily member 11b	Homo sapiens	138-141
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	25(oh)2d3	93-102	TNF superfamily member 11	Homo sapiens	142-147
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	25(oh)2d3	93-102	interleukin 6	Homo sapiens	187-191
24348674-4	2013	MH7A cells were stimulated with IL1 beta and then treated with different concentrations of 1,25(OH)2D3 for 48 h. A significantly elevated OPG/RANKL ratio and markedly decreased levels of IL-6 and TNF beta mRNA expression in cells and IL-6 protein in supernatants were observed in IL1 beta -induced MH7A in the presence of 1,25(OH)2D3 compared with those in the absence of it.	25(oh)2d3	93-102	lymphotoxin alpha	Homo sapiens	196-204
20693691-1	2010	TEI-9647 antagonizes vitamin D receptor (VDR) mediated genomic actions of 1alpha,25(OH)2D3 in human cells but is agonistic in rodent cells.	25(oh)2d3	81-90	vitamin D receptor	Homo sapiens	21-39
20693691-1	2010	TEI-9647 antagonizes vitamin D receptor (VDR) mediated genomic actions of 1alpha,25(OH)2D3 in human cells but is agonistic in rodent cells.	25(oh)2d3	81-90	vitamin D receptor	Homo sapiens	41-44
20223287-5	2010	ROCK and MSK inhibition also abrogates the induction of 1,25(OH)2D3 24-hydroxylase (CYP24), E-cadherin, and vinculin and the repression of cyclin D1 by 1,25(OH)2D3.	25(oh)2d3	58-67	salt inducible kinase 1	Homo sapiens	9-12
18519790-2	2008	In this study, we show that the Iroquois homeobox gene 5 (Irx5) is down-regulated by 1,25(OH)2D3 in human prostate cancer samples from patients randomly assigned to receive weekly high-dose 1,25(OH)2D3 or placebo before radical prostatectomy.	25(oh)2d3	87-96	iroquois homeobox 5	Homo sapiens	32-56
20398757-0	2010	The role of cubilin gene polymorphisms and their influence on 25(OH)D3 and 1,25(OH)2D3 plasma levels in type 1 diabetes patients.	25(oh)2d3	77-86	cubilin	Homo sapiens	12-19
19667160-1	2009	Tissue-specific expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alpha-OHase) and vitamin D-hydroxylase (24-OHase) may act as the pivotal link between 25-hydroxyvitamin D3 (25(OH)D3) serum levels and the anticancer effects of 1,25-dihydoxyvitamin D3 (1,25(OH)2D3) and alternative splicing of the enzymes may regulate their biological function.	25(oh)2d3	259-268	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	111-119
19662683-3	2009	Here we report that 1alpha,25(OH)2D3 induced vitamin D receptor (VDR) binding to, and activation of, the CST5 promoter and increased CST5 RNA and protein levels in human colon cancer cells.	25(oh)2d3	27-36	vitamin D receptor	Homo sapiens	45-63
19662683-3	2009	Here we report that 1alpha,25(OH)2D3 induced vitamin D receptor (VDR) binding to, and activation of, the CST5 promoter and increased CST5 RNA and protein levels in human colon cancer cells.	25(oh)2d3	27-36	vitamin D receptor	Homo sapiens	65-68
19662683-3	2009	Here we report that 1alpha,25(OH)2D3 induced vitamin D receptor (VDR) binding to, and activation of, the CST5 promoter and increased CST5 RNA and protein levels in human colon cancer cells.	25(oh)2d3	27-36	cystatin D	Homo sapiens	105-109
19662683-3	2009	Here we report that 1alpha,25(OH)2D3 induced vitamin D receptor (VDR) binding to, and activation of, the CST5 promoter and increased CST5 RNA and protein levels in human colon cancer cells.	25(oh)2d3	27-36	cystatin D	Homo sapiens	133-137
19662683-7	2009	CST5 knockdown using shRNA abrogated the antiproliferative effect of 1alpha,25(OH)2D3, attenuated E-cadherin expression, and increased c-MYC expression.	25(oh)2d3	76-85	cystatin D	Homo sapiens	0-4
18767073-2	2008	The vitamin D metabolite 1alpha,25(OH)2D3 mediates growth inhibitory signaling via activation of the vitamin D receptor (VDR), a ligand dependent transcription factor.	25(oh)2d3	32-41	vitamin D receptor	Homo sapiens	101-119
18767073-2	2008	The vitamin D metabolite 1alpha,25(OH)2D3 mediates growth inhibitory signaling via activation of the vitamin D receptor (VDR), a ligand dependent transcription factor.	25(oh)2d3	32-41	vitamin D receptor	Homo sapiens	121-124
19667162-10	2009	It can be speculated whether increased expression of CYP27B1 splice variants that lack enzymatic activity (Hyd-V3/V5) may result in a reduction of enzymatic activity and in reduced synthesis of 1,25(OH)2D3.	25(oh)2d3	196-205	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	53-60
18519790-2	2008	In this study, we show that the Iroquois homeobox gene 5 (Irx5) is down-regulated by 1,25(OH)2D3 in human prostate cancer samples from patients randomly assigned to receive weekly high-dose 1,25(OH)2D3 or placebo before radical prostatectomy.	25(oh)2d3	87-96	iroquois homeobox 5	Homo sapiens	58-62
17426122-1	2007	The human 25-hydroxyvitamin D3 (25(OH)D3) 1alpha-hydroxylase, which is encoded by the CYP27B1 gene, catalyzes the metabolic activation of the 25(OH)D3 into 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the most biologically potent vitamin D3 metabolite.	25(oh)2d3	194-203	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	86-93
17551101-4	2007	Further analysis showed that this was a result of decreased production of nitric oxide by 1alpha,25(OH)2D3-treated macrophages due to Vdr-dependent up-regulation of arginase 1 expression, which overrides NO production by Nos2.	25(oh)2d3	97-106	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	134-137
17070129-3	2007	2MD analogs were 100 times as potent as 1alpha,25(OH)2D3 in stimulating the formation of osteoclasts in vitro and in inducing the expression of receptor activator of NF-kappaB ligand (RANKL) and 25-hydroxyvitamin D3-24 hydroxylase mRNAs in osteoblasts.	25(oh)2d3	47-56	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	144-182
17449905-9	2007	In contrast, an E-cadherin blocking antibody inhibits 1,25(OH)2D3-induced differentiation of SW480-ADH cells and DKK-1 gene expression.	25(oh)2d3	56-65	cadherin 1	Homo sapiens	16-26
16215981-5	2006	1Alpha,25(OH)2D3 was able to dephosphorylate/activate the ubiquitous cytosolic tyrosine kinase c-Src in C2C12 cells and studies with specific inhibitors imply that Src participates in hormone induced-p38 activation.	25(oh)2d3	7-16	Rous sarcoma oncogene	Mus musculus	97-100
16886677-6	2006	Human normal and cancer colon epithelial cells express VDR and the key enzymes involved in 1,25(OH)2D3 synthesis and degradation and are, thus, responsive to the hormone.	25(oh)2d3	93-102	vitamin D receptor	Homo sapiens	55-58
16617161-8	2006	A three-dimensional model of CYP24A1 indicated that the A-ring and triene part of 1alpha,25(OH)2D3 could be located close to amino acid residues at positions 416 and 500, respectively.	25(oh)2d3	89-98	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	29-36
16368784-9	2006	Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH)2D3 occurs at the postclonal expansion stages and involves direct suppression of C/EBPalpha and PPARgamma upregulation, antagonization of PPARgamma activity, and stabilization of the inhibitory VDR protein.	25(oh)2d3	90-99	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	177-187
16368784-9	2006	Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH)2D3 occurs at the postclonal expansion stages and involves direct suppression of C/EBPalpha and PPARgamma upregulation, antagonization of PPARgamma activity, and stabilization of the inhibitory VDR protein.	25(oh)2d3	90-99	peroxisome proliferator activated receptor gamma	Mus musculus	192-201
16368784-9	2006	Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH)2D3 occurs at the postclonal expansion stages and involves direct suppression of C/EBPalpha and PPARgamma upregulation, antagonization of PPARgamma activity, and stabilization of the inhibitory VDR protein.	25(oh)2d3	90-99	peroxisome proliferator activated receptor gamma	Mus musculus	234-243
16368784-9	2006	Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH)2D3 occurs at the postclonal expansion stages and involves direct suppression of C/EBPalpha and PPARgamma upregulation, antagonization of PPARgamma activity, and stabilization of the inhibitory VDR protein.	25(oh)2d3	90-99	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	290-293
16509569-1	2006	The plethora of actions of 1alpha,25(OH)2D3 in various systems suggested wide clinical applications of vitamin D nuclear receptor (VDR) ligands in treatments of inflammation, dermatological indication, osteoporosis, cancers, and autoimmune diseases.	25(oh)2d3	34-43	vitamin D receptor	Homo sapiens	103-129
16509569-1	2006	The plethora of actions of 1alpha,25(OH)2D3 in various systems suggested wide clinical applications of vitamin D nuclear receptor (VDR) ligands in treatments of inflammation, dermatological indication, osteoporosis, cancers, and autoimmune diseases.	25(oh)2d3	34-43	vitamin D receptor	Homo sapiens	131-134
16215981-5	2006	1Alpha,25(OH)2D3 was able to dephosphorylate/activate the ubiquitous cytosolic tyrosine kinase c-Src in C2C12 cells and studies with specific inhibitors imply that Src participates in hormone induced-p38 activation.	25(oh)2d3	7-16	Rous sarcoma oncogene	Mus musculus	164-167
16215981-5	2006	1Alpha,25(OH)2D3 was able to dephosphorylate/activate the ubiquitous cytosolic tyrosine kinase c-Src in C2C12 cells and studies with specific inhibitors imply that Src participates in hormone induced-p38 activation.	25(oh)2d3	7-16	mitogen-activated protein kinase 14	Mus musculus	200-203
16215981-6	2006	Of relevance, 1alpha,25(OH)2D3 induced in the C2C12 line the stimulation of mitogen-activated protein kinase activating protein kinase 2 (MAPKAP-kinase 2) and subsequent phosphorylation of heat shock protein 27 (HSP27) in a p38 kinase activation-dependent manner.	25(oh)2d3	21-30	MAP kinase-activated protein kinase 2	Mus musculus	138-153
16215981-6	2006	Of relevance, 1alpha,25(OH)2D3 induced in the C2C12 line the stimulation of mitogen-activated protein kinase activating protein kinase 2 (MAPKAP-kinase 2) and subsequent phosphorylation of heat shock protein 27 (HSP27) in a p38 kinase activation-dependent manner.	25(oh)2d3	21-30	heat shock protein 1	Mus musculus	189-210
16215981-6	2006	Of relevance, 1alpha,25(OH)2D3 induced in the C2C12 line the stimulation of mitogen-activated protein kinase activating protein kinase 2 (MAPKAP-kinase 2) and subsequent phosphorylation of heat shock protein 27 (HSP27) in a p38 kinase activation-dependent manner.	25(oh)2d3	21-30	heat shock protein 1	Mus musculus	212-217
16215981-6	2006	Of relevance, 1alpha,25(OH)2D3 induced in the C2C12 line the stimulation of mitogen-activated protein kinase activating protein kinase 2 (MAPKAP-kinase 2) and subsequent phosphorylation of heat shock protein 27 (HSP27) in a p38 kinase activation-dependent manner.	25(oh)2d3	21-30	mitogen-activated protein kinase 14	Mus musculus	224-227
16215981-8	2006	1Alpha,25(OH)2D3 also promotes the phosphorylation of c-jun N-terminal protein kinases (JNK 1/2), the response is fast (0.5-1 min) and maximal phosphorylation of the enzyme is observed at physiological doses of 1alpha,25(OH)2D3 (1 nM).	25(oh)2d3	7-16	mitogen-activated protein kinase 8	Mus musculus	88-95
16215981-8	2006	1Alpha,25(OH)2D3 also promotes the phosphorylation of c-jun N-terminal protein kinases (JNK 1/2), the response is fast (0.5-1 min) and maximal phosphorylation of the enzyme is observed at physiological doses of 1alpha,25(OH)2D3 (1 nM).	25(oh)2d3	218-227	mitogen-activated protein kinase 8	Mus musculus	88-95
16424941-2	2006	Using osteoprotegerin-deficient mice, which exhibit severe osteoporosis due to excessive receptor activator of NF-kappaB ligand/receptor activator of NF-kappaB (RANKL/RANK) stimulation, we show herein that oral treatment of these mice with 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] inhibited bone resorption and prevented bone loss, suggesting that VDR counters RANKL/RANK signaling.	25(oh)2d3	278-287	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	161-166
16424941-3	2006	In M-CSF-dependent osteoclast precursor cells isolated from mouse bone marrow, 1alpha,25(OH)2D3 potently and dose-dependently inhibited their differentiation into multinucleate osteoclasts induced by RANKL.	25(oh)2d3	86-95	colony stimulating factor 1 (macrophage)	Mus musculus	3-8
16424941-3	2006	In M-CSF-dependent osteoclast precursor cells isolated from mouse bone marrow, 1alpha,25(OH)2D3 potently and dose-dependently inhibited their differentiation into multinucleate osteoclasts induced by RANKL.	25(oh)2d3	86-95	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	200-205
16848737-1	2006	The vitamin D receptor, a member of the nuclear receptor subgroup NR1I, is regulated by 1alpha,25(OH)2D3 to control calcium metabolism, cell proliferation and differentiation and immunomodulation.	25(oh)2d3	95-104	vitamin D receptor	Homo sapiens	4-22
16118315-4	2005	We show here that 1alpha,25(OH)2D3 can selectively suppress key effector functions of IFN-gamma-activated macrophages.	25(oh)2d3	25-34	interferon gamma	Homo sapiens	86-95
16007183-4	2005	1alpha,25(OH)2D3 induced epithelial differentiation in SW480-ADH human colon carcinoma cell line by promoting expression of the proteins implicated in adherent junction formation, including E-cadherin, and by inhibiting beta-catenin transcriptional activity.	25(oh)2d3	7-16	cadherin 1	Homo sapiens	190-200
16007183-4	2005	1alpha,25(OH)2D3 induced epithelial differentiation in SW480-ADH human colon carcinoma cell line by promoting expression of the proteins implicated in adherent junction formation, including E-cadherin, and by inhibiting beta-catenin transcriptional activity.	25(oh)2d3	7-16	catenin beta 1	Homo sapiens	220-232
16007183-9	2005	In addition, we showed that 1alpha,25(OH)2D3 changed the levels of the inducer of angiogenesis, vascular endothelial growth factor and the potent antiangiogenic factor thrombospondin-1, leading to a balanced change in the angiogenic potential of SW480-ADH human colon carcinoma cells.	25(oh)2d3	35-44	vascular endothelial growth factor A	Homo sapiens	96-130
16007183-9	2005	In addition, we showed that 1alpha,25(OH)2D3 changed the levels of the inducer of angiogenesis, vascular endothelial growth factor and the potent antiangiogenic factor thrombospondin-1, leading to a balanced change in the angiogenic potential of SW480-ADH human colon carcinoma cells.	25(oh)2d3	35-44	thrombospondin 1	Homo sapiens	168-184
15574355-3	2005	Upon analyses of the metabolites of vitamin D3 by the reconstituted system, CYP27A1 surprisingly produced at least seven forms of minor metabolites including 1alpha,25(OH)2D3 in addition to the major metabolite 25(OH)D3.	25(oh)2d3	165-174	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	76-83
15840226-4	2005	ELISA was done to examine the effect of 1alpha,25(OH)2D3 on the activity of MMP-2.	25(oh)2d3	47-56	matrix metallopeptidase 2	Homo sapiens	76-81
15754350-4	2005	METHODS: We have assessed the requirement for endogenous androgens in 1,25(OH)2D3 mediated growth inhibition of AR+ prostate cancer cell lines.	25(oh)2d3	72-81	androgen receptor	Homo sapiens	112-114
15574355-9	2005	CYP24A1 expressed in E. coli showed a remarkable metabolic processes of 25(OH)D3 and 1alpha,25(OH)2D3.	25(oh)2d3	92-101	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
15488475-6	2004	Production of the metabolites including the 25-hydroxylated ones was detectable only when CYP24A1 activity was induced in keratinocytes 1alpha,25(OH)2D3.	25(oh)2d3	143-152	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	90-97
15474498-0	2004	Phosphorylation of human vitamin D receptor serine-182 by PKA suppresses 1,25(OH)2D3-dependent transactivation.	25(oh)2d3	75-84	vitamin D receptor	Homo sapiens	25-43
15389882-10	2004	While the combination further increased acetylation of H4 on the RANKL locus, surprisingly, TSA inhibited 1,25(OH)2D3-induced RANKL mRNA expression by 70% at all doses of 1 ,25(OH)2D3 studied.	25(oh)2d3	108-117	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	126-131
15368364-3	2004	In addition to regulating gene transcription via its specific intracellular receptor (vitamin D receptor, VDR), 1alpha,25(OH)2D3 induces rapid, non-transcriptional responses involving activation of transmembrane signal transduction pathways, like growth factors and peptide hormones.	25(oh)2d3	119-128	vitamin D receptor	Homo sapiens	106-109
15203106-6	2004	Transfection with anti-VDR antisense ODNs diminished 1alpha,25(OH)2D3-dependent Ca2+ and Mn2+ influx.	25(oh)2d3	60-69	vitamin D receptor	Homo sapiens	23-26
15203106-5	2004	Spectrofluorimetric measurements in Fura-2 loaded cells showed reduced CCE and Mn2+ entry in response to either thapsigargin or 1alpha,25(OH)2D3 upon transfection with anti-TRPC3/6/7 antisense oligodeoxynucleotides (ODNs).	25(oh)2d3	135-144	transient receptor potential cation channel subfamily C member 3	Homo sapiens	173-178
15293309-16	2004	On TPS 10(-7) M 1alpha,25(OH)2D3 increased OPG 350%.	25(oh)2d3	23-32	TNF receptor superfamily member 11b	Homo sapiens	43-46
15300237-8	2004	Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45alpha induction by 1alpha,25(OH)2D3 alone became very significantly enhanced.	25(oh)2d3	150-159	nuclear receptor corepressor 2	Homo sapiens	30-34
15300237-8	2004	Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45alpha induction by 1alpha,25(OH)2D3 alone became very significantly enhanced.	25(oh)2d3	150-159	chromobox 8	Homo sapiens	45-49
15300237-8	2004	Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45alpha induction by 1alpha,25(OH)2D3 alone became very significantly enhanced.	25(oh)2d3	150-159	growth arrest and DNA damage inducible alpha	Homo sapiens	118-129
15709693-0	2004	1alpha,25(OH)2D3 induces capacitative calcium entry involving a TRPC3 protein in skeletal muscle and osteoblastic cells.	25(oh)2d3	7-16	transient receptor potential cation channel, subfamily C, member 3	Rattus norvegicus	64-69
15450206-2	2004	MMP-3 is released from these extracellular organelles by the direct action of 1alpha,25(OH)2D3 via activation of phospholipase A2 (PLA2), resulting in local production of lysophospholipids and matrix vesicle membrane destabilization.	25(oh)2d3	85-94	matrix metallopeptidase 3	Rattus norvegicus	0-5
15450206-2	2004	MMP-3 is released from these extracellular organelles by the direct action of 1alpha,25(OH)2D3 via activation of phospholipase A2 (PLA2), resulting in local production of lysophospholipids and matrix vesicle membrane destabilization.	25(oh)2d3	85-94	phospholipase A2 group IB	Rattus norvegicus	113-129
15450206-2	2004	MMP-3 is released from these extracellular organelles by the direct action of 1alpha,25(OH)2D3 via activation of phospholipase A2 (PLA2), resulting in local production of lysophospholipids and matrix vesicle membrane destabilization.	25(oh)2d3	85-94	phospholipase A2 group IB	Rattus norvegicus	131-135
15042599-10	2004	The up-regulation of IGFBP-3 gene has been shown to be crucial in 1,25(OH)2D3-mediated inhibition of LNCaP cell growth.	25(oh)2d3	68-77	insulin like growth factor binding protein 3	Homo sapiens	21-28
15042604-5	2004	In addition, we also studied the effects of 1,25(OH)2D3 on TGFbeta signaling and receptor expression.	25(oh)2d3	46-55	transforming growth factor beta 1	Homo sapiens	59-66
14635194-0	2003	Membrane actions of vitamin D metabolites 1alpha,25(OH)2D3 and 24R,25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice.	25(oh)2d3	49-58	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	127-145
14635194-0	2003	Membrane actions of vitamin D metabolites 1alpha,25(OH)2D3 and 24R,25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice.	25(oh)2d3	67-76	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	127-145
12955156-13	2003	Conclusively, these findings suggest that NKCC1 in osteoblasts has a pivotal role in 1alpha,25(OH)2D3-induced osteoclastogenesis partly via the phosphorylation of JNK.	25(oh)2d3	92-101	solute carrier family 12, member 2	Mus musculus	42-47
12955156-13	2003	Conclusively, these findings suggest that NKCC1 in osteoblasts has a pivotal role in 1alpha,25(OH)2D3-induced osteoclastogenesis partly via the phosphorylation of JNK.	25(oh)2d3	92-101	mitogen-activated protein kinase 8	Mus musculus	163-166
11805100-0	2002	1alpha,25(OH)2D3 regulates chondrocyte matrix vesicle protein kinase C (PKC) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis.	25(oh)2d3	7-16	proline rich transmembrane protein 2	Homo sapiens	54-70
12899515-9	2003	We believe that a combination of elevated co-repressor level with reduced VDR content can cause 1alpha,25(OH)2D3 resistance.	25(oh)2d3	103-112	vitamin D receptor	Homo sapiens	74-77
12899517-1	2003	1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3) inhibits the expression of an immediate-early gene, IEX-1, which is involved in the regulation of cellular growth and apoptosis in a variety of cells.	25(oh)2d3	38-47	immediate early response 3	Homo sapiens	101-106
12899518-1	2003	Calcitriol (1alpha,25(OH)2D3), the hormonally active form of vitamin D3 (D3) is produced by a cascade of reactions, including photochemical D3 synthesis in the skin and subsequent hydroxylation at the C-25 atom in the liver and finally at C-1alpha position in the kidney.	25(oh)2d3	19-28	endogenous retrovirus group K member 1	Homo sapiens	239-247
12211430-6	2002	Enhanced VEGF expression also was evident in growth plate chondrocytes and osteoblasts in the tibia of juvenile mice treated systemically with 1alpha,25(OH)2D3.	25(oh)2d3	150-159	vascular endothelial growth factor A	Mus musculus	9-13
12016462-13	2002	In the case of F6-D3, peaks of F6-D3 and 26,27-hexafluoro-23-oxo-1a,25(OH)2D3(23-oxo-F6) were clearly detected, the latter being about 4 times higher than the former.	25(oh)2d3	68-77	iodothyronine deiodinase 3	Homo sapiens	15-20
12899529-11	2003	We found that 1alpha,25(OH)2D3 and 19-nor-1alpha,25(OH)2D2 caused similar dose-dependent inhibition in 3H-thymidine incorporation into DNA in prostate cells and behaved similarly in the CAT reporter gene transactivation assay in PC-3/VDR cells.	25(oh)2d3	21-30	vitamin D receptor	Rattus norvegicus	234-237
11805100-0	2002	1alpha,25(OH)2D3 regulates chondrocyte matrix vesicle protein kinase C (PKC) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis.	25(oh)2d3	7-16	proline rich transmembrane protein 2	Homo sapiens	72-75
11805100-0	2002	1alpha,25(OH)2D3 regulates chondrocyte matrix vesicle protein kinase C (PKC) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis.	25(oh)2d3	7-16	proline rich transmembrane protein 2	Homo sapiens	157-160
11256478-5	2001	Osteocalcin (OC) production in HOB-DEX cells was stimulated 1.3 to 1.4-fold by 1alpha,25(OH)2D3 and 1alpha,25(OH)2-16-ene-D3 at a concentration of 0.01 nM, with E2 inhibiting the effect of 1alpha,25(OH)2-16-ene-D3.	25(oh)2d3	86-95	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
11922564-9	2002	CONCLUSIONS: Taking into account the lowest CsA dose (1 ng/ml), the highest synergistic inhibition in the proliferation of T lymphocytes prepared from ulcerative colitis patients was found combining CsA and 10 nM of 1,25(OH)2D3 or 10 nM of EB 1089 or KH 1060 at the three concentrations.	25(oh)2d3	218-227	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	44-47
11922564-9	2002	CONCLUSIONS: Taking into account the lowest CsA dose (1 ng/ml), the highest synergistic inhibition in the proliferation of T lymphocytes prepared from ulcerative colitis patients was found combining CsA and 10 nM of 1,25(OH)2D3 or 10 nM of EB 1089 or KH 1060 at the three concentrations.	25(oh)2d3	218-227	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	199-202
11450704-16	2001	Inhibition of phospholipase A2 with quinacrine blocked the 1alpha,25(OH)2D3-dependent effect.	25(oh)2d3	66-75	phospholipase A2 group IB	Homo sapiens	14-30
11450704-17	2001	These results suggest that the ability of 1alpha,25(OH)2D3-treated matrix vesicles to activate small latent TGF-beta1 is via action of the secosteroid on the matrix vesicle membrane, not on the enzymes responsible for activating latent TGF-beta1.	25(oh)2d3	49-58	transforming growth factor beta 1	Homo sapiens	108-117
11450704-17	2001	These results suggest that the ability of 1alpha,25(OH)2D3-treated matrix vesicles to activate small latent TGF-beta1 is via action of the secosteroid on the matrix vesicle membrane, not on the enzymes responsible for activating latent TGF-beta1.	25(oh)2d3	49-58	transforming growth factor beta 1	Homo sapiens	236-245
11450704-18	2001	Because matrix vesicles isolated from growth zone chondrocytes have been shown to contain increased phospholipase A2 activity after treatment with 1alpha,25(OH)2D3, it is likely that this secosteroid promotes loss of membrane integrity through phospholipase A2-dependent formation of lysophospholipids, resulting in the release of MMP-3 into the matrix, where latent TGF-beta1 is stored.	25(oh)2d3	154-163	phospholipase A2 group IB	Homo sapiens	100-116
10549855-6	1999	Furthermore, the enhanced transmembrane Ca2+ influx induced by 1alpha,25(OH)2D3 (10(-8)M) or OCT (10(-8)M) was completely blocked by pre-treatment with the respective 1beta epimer [1beta,25(OH)2D3 and 1beta-OCT] at equal concentration.	25(oh)2d3	70-79	plexin A2	Homo sapiens	207-210
10612418-3	1999	1Alpha,25(OH)2D3, is biosynthesized from cholesterol, and at the final biosynthesis step, 25-hydroxyvitamin D3 1alpha-hydroxylase [1alpha(OH)ase] in kidney conducts 1alpha-hydroxylation of 25(OH)2D3.	25(oh)2d3	7-16	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	90-129
10612418-3	1999	1Alpha,25(OH)2D3, is biosynthesized from cholesterol, and at the final biosynthesis step, 25-hydroxyvitamin D3 1alpha-hydroxylase [1alpha(OH)ase] in kidney conducts 1alpha-hydroxylation of 25(OH)2D3.	25(oh)2d3	7-16	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	131-144
10612418-3	1999	1Alpha,25(OH)2D3, is biosynthesized from cholesterol, and at the final biosynthesis step, 25-hydroxyvitamin D3 1alpha-hydroxylase [1alpha(OH)ase] in kidney conducts 1alpha-hydroxylation of 25(OH)2D3.	25(oh)2d3	189-198	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	90-129
10612418-3	1999	1Alpha,25(OH)2D3, is biosynthesized from cholesterol, and at the final biosynthesis step, 25-hydroxyvitamin D3 1alpha-hydroxylase [1alpha(OH)ase] in kidney conducts 1alpha-hydroxylation of 25(OH)2D3.	25(oh)2d3	189-198	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	131-144
12067069-6	2001	The cooperative actions of TGF-beta and 1alpha,25(OH)2D3 can be synergistic or antagonistic.	25(oh)2d3	47-56	transforming growth factor beta 1	Homo sapiens	27-35
11042697-9	2000	Examination of other breast and prostate cancer cell lines revealed that sensitivity to the anti-proliferative effects of 1alpha, 25(OH)2D3 was strongly associated with an ability to modulate BRCA1 protein.	25(oh)2d3	130-139	BRCA1 DNA repair associated	Homo sapiens	192-197
10549855-6	1999	Furthermore, the enhanced transmembrane Ca2+ influx induced by 1alpha,25(OH)2D3 (10(-8)M) or OCT (10(-8)M) was completely blocked by pre-treatment with the respective 1beta epimer [1beta,25(OH)2D3 and 1beta-OCT] at equal concentration.	25(oh)2d3	187-196	plexin A2	Homo sapiens	93-96
10510206-7	1999	The increased sensitivity of osteoclast precursors to 1,25(OH)2D3 is mediated through the vitamin D receptor (VDR), since 24-hydroxylase activity is also up-regulated at concentrations of 1,25(OH)2D3 that are one log less than that needed to induce 24-hydroxylase activity in osteoclast precursors from normals.	25(oh)2d3	56-65	vitamin D receptor	Homo sapiens	90-108
10510206-7	1999	The increased sensitivity of osteoclast precursors to 1,25(OH)2D3 is mediated through the vitamin D receptor (VDR), since 24-hydroxylase activity is also up-regulated at concentrations of 1,25(OH)2D3 that are one log less than that needed to induce 24-hydroxylase activity in osteoclast precursors from normals.	25(oh)2d3	56-65	vitamin D receptor	Homo sapiens	110-113
10405337-6	1999	Further, the CaSR agonist neomycin also concentration dependently inhibited 1,25(OH)2D3- or hPTH(1-34)-induced Ocl formation.	25(oh)2d3	78-87	calcium-sensing receptor	Mus musculus	13-17
10223184-8	1999	On the other hand, co-transfection of a VDR expression vector could restore 1,25(OH)2D3-induced VDRE transcription in HBL100 cells.	25(oh)2d3	78-87	vitamin D receptor	Homo sapiens	40-43
10393981-9	1999	Conversion of serum [3H]1alpha,25(OH)2D3 from 25-hydroxy[3H]vitamin D3 in vivo was also greatly increased by the injection of CT into sham-TPTX rats and normocalcemic TPTX rats, but not into hypocalcemic TPTX rats.	25(oh)2d3	31-40	calcitonin-related polypeptide alpha	Rattus norvegicus	126-128
10321905-3	1999	Recently, we reported that 1alpha,25(OH)2D3 is also metabolized into 1alpha,25-dihydroxy-3-epi-vitamin D3 [1alpha,25(OH)2-3-epi-D3] through the carbon 3 (C-3) epimerization pathway in human keratinocytes, human colon carcinoma cells (Caco-2), and bovine parathyroid cells.	25(oh)2d3	34-43	complement C3	Homo sapiens	144-157
10218975-0	1999	Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals.	25(oh)2d3	139-148	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	47-86
10218975-1	1999	Reflecting the prime role of 1alpha,25(OH)2D3 in calcium homeostasis, the activity of 25-hydroxyvitamin D3 1alpha-hydroxylase, a key enzyme for 1alpha,25(OH)2D3 biosynthesis, is tightly regulated by 1alpha,25(OH)2D3, PTH and calcitonin.	25(oh)2d3	36-45	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	86-125
10218975-1	1999	Reflecting the prime role of 1alpha,25(OH)2D3 in calcium homeostasis, the activity of 25-hydroxyvitamin D3 1alpha-hydroxylase, a key enzyme for 1alpha,25(OH)2D3 biosynthesis, is tightly regulated by 1alpha,25(OH)2D3, PTH and calcitonin.	25(oh)2d3	151-160	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	86-125
10218975-1	1999	Reflecting the prime role of 1alpha,25(OH)2D3 in calcium homeostasis, the activity of 25-hydroxyvitamin D3 1alpha-hydroxylase, a key enzyme for 1alpha,25(OH)2D3 biosynthesis, is tightly regulated by 1alpha,25(OH)2D3, PTH and calcitonin.	25(oh)2d3	151-160	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	86-125
10198344-5	1999	Removal of Ca2+ from the medium, as well as preincubation of cells with Go-6976, an inhibitor of Ca2+-dependent PKC isoforms, significantly reduced the stimulation of PLD by 1,25(OH)2D3 or TPA.	25(oh)2d3	176-185	protein kinase C alpha	Homo sapiens	112-115
10198344-5	1999	Removal of Ca2+ from the medium, as well as preincubation of cells with Go-6976, an inhibitor of Ca2+-dependent PKC isoforms, significantly reduced the stimulation of PLD by 1,25(OH)2D3 or TPA.	25(oh)2d3	176-185	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	167-170
10049715-6	1999	The adhesion assay demonstrate that the number of adherent cells treated with 1, 25(OH)2D3 is significantly lower than that untreated on VCAM-1-coated wells.	25(oh)2d3	81-90	vascular cell adhesion molecule 1	Homo sapiens	137-143
10375029-4	1999	Inhibiting 1alpha,25(OH)2D3 or 1alpha,25(OH)2-20-epi-D3 metabolism, by the 25(OH)D3-24-hydroxylase inhibitor ketoconazole, abolished hyperproliferation of CD14 negative cells.	25(oh)2d3	18-27	CD14 molecule	Homo sapiens	155-159
9649179-8	1998	This was confirmed by the finding that splenocytes from 1,25(OH)2D3-treated mice were less capable of transferring diabetes in young, irradiated NOD mice, and by the demonstration of lower Th1 cytokine levels in the pancreases of 1,25(OH)2D3-treated, cyclophosphamide-injected mice.	25(oh)2d3	58-67	negative elongation factor complex member C/D, Th1l	Mus musculus	189-192
10025902-5	1999	Like PMA, bryostatin-1 synergistically interacted with 1alpha,25(OH)2D3 to stimulate ALP expression 30-fold over the control (P < 0.001) and further promote appearance of monocyte/macrophage-like cells.	25(oh)2d3	62-71	alkaline phosphatase, placental	Homo sapiens	85-88
9881643-3	1998	Thus, an ideal analogue of 1alpha,25(OH)2D3 for therapeutic applications has been considered to be one which has a high binding affinity for VDR, thus forming a stable VDR/RXR complex, and binding strongly to VDRE.	25(oh)2d3	34-43	vitamin D receptor	Homo sapiens	141-144
9881643-3	1998	Thus, an ideal analogue of 1alpha,25(OH)2D3 for therapeutic applications has been considered to be one which has a high binding affinity for VDR, thus forming a stable VDR/RXR complex, and binding strongly to VDRE.	25(oh)2d3	34-43	vitamin D receptor	Homo sapiens	168-171
9881643-3	1998	Thus, an ideal analogue of 1alpha,25(OH)2D3 for therapeutic applications has been considered to be one which has a high binding affinity for VDR, thus forming a stable VDR/RXR complex, and binding strongly to VDRE.	25(oh)2d3	34-43	retinoid X receptor alpha	Homo sapiens	172-175
9837769-4	1998	In contrast, the expression of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) mRNA was inhibited by 1alpha,25(OH)2D3 and dexamethasone similarly in all three types of calvarial cells.	25(oh)2d3	124-133	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	85-88
9837769-4	1998	In contrast, the expression of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) mRNA was inhibited by 1alpha,25(OH)2D3 and dexamethasone similarly in all three types of calvarial cells.	25(oh)2d3	124-133	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	89-93
9791001-3	1998	In sub-confluent keratinocyte cultures, the addition of 1alpha,25(OH)2D3, in amounts that induce growth arrest, reduces IEX-1 mRNA concentrations.	25(oh)2d3	63-72	immediate early response 3	Homo sapiens	120-125
9770350-5	1998	However, the same concentration of 24R,25(OH)2D3 showed stimulatory effects on osteocalcin synthesis in the presence of 10(-9) M 1, 25(OH)2D3.	25(oh)2d3	39-48	bone gamma-carboxyglutamate protein	Homo sapiens	79-90
9770350-8	1998	These observations suggest that 24R,25(OH)2D3 has a unique activity of increasing cGMP contents in osteoblastic cells, and that the increase in cGMP contents may lead to the cooperative effect of 24R,25(OH)2D3 with 1, 25(OH)2D3 on osteocalcin synthesis.	25(oh)2d3	36-45	bone gamma-carboxyglutamate protein	Homo sapiens	231-242
9111166-4	1997	Sorted CD14-positive HL-60 cells, treated with 1alpha,25(OH)2D3 for 7 days, reverted to CD14-negative cells and promyelocyte-like cells if 1alpha,25(OH)2D3 was removed from the medium.	25(oh)2d3	54-63	CD14 molecule	Homo sapiens	7-11
9459143-5	1998	HU also enhanced the morphological maturation and expression of CD11b and CD14 in cells treated with 1,25(OH)2D3.	25(oh)2d3	103-112	integrin subunit alpha M	Homo sapiens	64-69
9459143-5	1998	HU also enhanced the morphological maturation and expression of CD11b and CD14 in cells treated with 1,25(OH)2D3.	25(oh)2d3	103-112	CD14 molecule	Homo sapiens	74-78
9443788-9	1998	The IGF-I effect was completely blocked by 1,25(OH)2D3.	25(oh)2d3	45-54	insulin-like growth factor 1	Mus musculus	4-9
9383703-2	1997	On the other hand, functional relationships between the activities of c-src and 1,25(OH)2D3 are as yet unknown.	25(oh)2d3	82-91	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-75
9088565-8	1997	Our results show that the sterol hormone 1,25(OH)2D3, causes a decrease in the proliferation of mouse neuroblastoma cells through alterations in the expression of NGF.	25(oh)2d3	43-52	nerve growth factor	Mus musculus	163-166
9556133-8	1998	Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody.	25(oh)2d3	47-56	interleukin 6	Mus musculus	106-110
9556133-8	1998	Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody.	25(oh)2d3	47-56	interleukin 6	Mus musculus	187-191
9556133-8	1998	Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody.	25(oh)2d3	47-56	interleukin 6	Mus musculus	187-191
9556133-10	1998	Our data provide evidence that 1alpha,25(OH)2D3 induces osteoclast-like cell formation, at least in part, in an IL-6-dependent mode of action, which is also subject to modulation by T3.	25(oh)2d3	38-47	interleukin 6	Mus musculus	112-116
9348179-4	1997	17beta-E2 significantly suppressed basal and 1alpha,25(OH)2D3-stimulated cellular production of interleukin (IL)-6.	25(oh)2d3	52-61	interleukin 6	Mus musculus	96-114
9348179-7	1997	However, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis nevertheless can be significantly reduced by a neutralizing monoclonal anti-IL-6 antibody.	25(oh)2d3	42-51	interleukin 6	Mus musculus	150-154
9134225-13	1997	One of the following cytokines (epidermal growth factor, transforming growth factor alpha, interleukin-1 alpha, interleukin-1 beta, interleukin-6, interleukin-8) was required for 1,25(OH)2D3 to suppress clonal growth and induce cell differentiation.	25(oh)2d3	181-190	interleukin 1 alpha	Homo sapiens	91-110
9134225-13	1997	One of the following cytokines (epidermal growth factor, transforming growth factor alpha, interleukin-1 alpha, interleukin-1 beta, interleukin-6, interleukin-8) was required for 1,25(OH)2D3 to suppress clonal growth and induce cell differentiation.	25(oh)2d3	181-190	interleukin 1 beta	Homo sapiens	112-130
9134225-13	1997	One of the following cytokines (epidermal growth factor, transforming growth factor alpha, interleukin-1 alpha, interleukin-1 beta, interleukin-6, interleukin-8) was required for 1,25(OH)2D3 to suppress clonal growth and induce cell differentiation.	25(oh)2d3	181-190	interleukin 6	Homo sapiens	132-145
9134225-13	1997	One of the following cytokines (epidermal growth factor, transforming growth factor alpha, interleukin-1 alpha, interleukin-1 beta, interleukin-6, interleukin-8) was required for 1,25(OH)2D3 to suppress clonal growth and induce cell differentiation.	25(oh)2d3	181-190	C-X-C motif chemokine ligand 8	Homo sapiens	147-160
9111166-4	1997	Sorted CD14-positive HL-60 cells, treated with 1alpha,25(OH)2D3 for 7 days, reverted to CD14-negative cells and promyelocyte-like cells if 1alpha,25(OH)2D3 was removed from the medium.	25(oh)2d3	54-63	CD14 molecule	Homo sapiens	88-92
9111166-4	1997	Sorted CD14-positive HL-60 cells, treated with 1alpha,25(OH)2D3 for 7 days, reverted to CD14-negative cells and promyelocyte-like cells if 1alpha,25(OH)2D3 was removed from the medium.	25(oh)2d3	146-155	CD14 molecule	Homo sapiens	7-11
9111166-4	1997	Sorted CD14-positive HL-60 cells, treated with 1alpha,25(OH)2D3 for 7 days, reverted to CD14-negative cells and promyelocyte-like cells if 1alpha,25(OH)2D3 was removed from the medium.	25(oh)2d3	146-155	CD14 molecule	Homo sapiens	88-92
8943395-10	1996	In HL-60 cells, which constitutively express the nuclear receptors, 1,25(OH)2D3 rapidly induced CD38 Ag and ectoenzyme activity.	25(oh)2d3	70-79	CD38 molecule	Homo sapiens	96-100
9137940-6	1997	The production of osteocalcin after stimulation with 1.25(OH)2D3 was about 60% lower in older donors (> 50 years) than in younger ones (< 40 years), regardless of gender.	25(oh)2d3	55-64	bone gamma-carboxyglutamate protein	Homo sapiens	18-29
8968029-4	1996	Instead, 1 nmol/L 1alpha,25(OH)2D3 increased ALP 1.4-fold (p < 0.05).	25(oh)2d3	25-34	alkaline phosphatase, placental	Homo sapiens	45-48
8968029-5	1996	In these cells, E2 enhanced 1alpha,25(OH)2D3-stimulated ALP activity (ANOVA, F = 51.22, p <0.0001), while inhibiting the effect of the analog.	25(oh)2d3	35-44	alkaline phosphatase, placental	Homo sapiens	56-59
9191975-1	1997	We previously reported that 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3] activates the human osteocalcin gene (hOC) through vitamin D receptor (VDR) and vitamin D responsive element (VDRE) in the same manner as 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2 D3] [17].	25(oh)2d3	60-69	bone gamma-carboxyglutamate protein	Homo sapiens	91-102
9191975-1	1997	We previously reported that 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3] activates the human osteocalcin gene (hOC) through vitamin D receptor (VDR) and vitamin D responsive element (VDRE) in the same manner as 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2 D3] [17].	25(oh)2d3	60-69	vitamin D receptor	Homo sapiens	122-140
9191975-1	1997	We previously reported that 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3] activates the human osteocalcin gene (hOC) through vitamin D receptor (VDR) and vitamin D responsive element (VDRE) in the same manner as 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2 D3] [17].	25(oh)2d3	60-69	vitamin D receptor	Homo sapiens	142-145
9191975-8	1997	In terms of VDR function, 24R,25(OH)2D3 was more potent in transactivation than in vitro binding.	25(oh)2d3	30-39	vitamin D receptor	Homo sapiens	12-15
8968029-1	1996	We compared the separate effects of 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) and its analog, 1alpha,25-dihydroxy-16ene,23yne-vitamin D3 (1alpha25(OH)2-16ene,23yne-D3), as well as their interactions with 17-beta estradiol (E2) in our human osteosarcoma SaOS-2 cell models representing two stages of differentiation, the SaOS+DEX and SaOS-DEX cells.	25(oh)2d3	74-83	iodothyronine deiodinase 3	Homo sapiens	63-65
8770693-7	1996	These results provide evidence for the hypothesis that both recruitment and chondrogenesis of chondroprogenitors are negatively regulated by 1,25(OH)2D3 via a VDR-mediated process in vivo.	25(oh)2d3	143-152	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	159-162
8892678-4	1996	The CD34+ cells from acute myeloid leukemia (AML) blasts were inhibited in a dose-dependent fashion by 1,25(OH)2D3 with an ED50 of 1.2 x 10(-9) M; and even more strikingly, 10(-10) M of EB1089 inhibited all clonal growth of human CD34+ leukemic colony-forming cells.	25(oh)2d3	105-114	CD34 molecule	Homo sapiens	4-8
8892678-4	1996	The CD34+ cells from acute myeloid leukemia (AML) blasts were inhibited in a dose-dependent fashion by 1,25(OH)2D3 with an ED50 of 1.2 x 10(-9) M; and even more strikingly, 10(-10) M of EB1089 inhibited all clonal growth of human CD34+ leukemic colony-forming cells.	25(oh)2d3	105-114	CD34 molecule	Homo sapiens	230-234
7593234-1	1995	We investigated the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on the expression of scavenger receptors in human monocytic cell line (THP-1 cells) treated for 24 h with 12-O-tetradecanoylphorbol-13-acetate (TPA) which induces their differentiation into macrophages.	25(oh)2d3	58-67	GLI family zinc finger 2	Homo sapiens	140-145
7867568-2	1995	In previous studies concerning the mechanism of 1 alpha,25(OH)2D3-stimulated rapid intestinal transport of Ca2+, a process termed transcaltachia, we assessed the ability of seven analogs of 1 alpha,25(OH)2D3 to initiate transcaltachia in the vitamin D-replete chick and bind in vitro to the classical nuclear chick intestinal receptor for 1 alpha,25(OH)2D3 (VDR).	25(oh)2d3	56-65	carbonic anhydrase 2	Gallus gallus	107-110
7947935-1	1994	In rat calvarial osteoblast-like cells and in clonal osteogenic sarcoma cells (UMR 106-01), 1,25-dihydroxyvitamin D-3 (1,25(OH)2D3) enhanced plasminogen activator (PA) activity and decreased PA inhibitor-1 (PAI-1) production over the same concentration range.	25(oh)2d3	121-130	serpin family E member 1	Rattus norvegicus	191-205
7947935-1	1994	In rat calvarial osteoblast-like cells and in clonal osteogenic sarcoma cells (UMR 106-01), 1,25-dihydroxyvitamin D-3 (1,25(OH)2D3) enhanced plasminogen activator (PA) activity and decreased PA inhibitor-1 (PAI-1) production over the same concentration range.	25(oh)2d3	121-130	serpin family E member 1	Rattus norvegicus	207-212